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Since the establishment of molecular biology until the present, a shift has taken 
place by which engineering of biology has increased in its scope, power, and influence. 
Synthetic biology is the latest term that advances the overall goal of engineering control 
of biological systems. Enabled by the recent progress in the ability to read and write 
nucleic acids, synthetic biology stands out in its desire for standardization of parts, 
processes, assays, and even organisms. This standardization has led to multiple successful 
outcomes which justify its utility. However, this standardization via synthetic biology is 
imbued with an implicit hubris: it may be that certain aspects of biological phenomena 
are too complex to lend themselves to systemization. Engineering biology, unlike other 
engineering disciplines, is not obviously governed by a simple series of equations but, 
rather, united by one universal theme: evolution happens.  
Because of this, much work has been done in order to study not just how 
evolution works and but also into controlling, accelerating, and biasing it in a laboratory 
setting. The former work can be generally classified as “evolutionary biology” and the 
latter called “directed evolution”. In this dissertation, work is presented which blurs the 
 vii 
line between evolutionary biology and directed evolution yielding unanticipated 
outcomes and new methods of biological control.  
Three projects are presented in which evolution of bacteriophage T7 is studied in 
response to rationally engineered design constraints. In the first, the predictability of 
bacteriophage T7 promoter evolution in response to a novel RNA polymerase is 
determined. In the second, the evolution of the entirety of the transcriptional apparatus of 
bacteriophage T7 is studied in the context of an evolutionarily adapted bacteriophage 
population. Finally, the construction, exploration, and optimization of a designed 
bacteriophage T7 life-cycling system reliant on proteases are described. Together, this 
work provides evidence that although the ability to rationally design biology is important, 
various ways to rationally control and direct evolution offer a complementary strategy to 
the systematization of synthetic biology. 
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 1 
INTRODUCTION 
 
Discovery, Classification, and Diversity of Bacteriophages 
Every good story has to begin somewhere. For bacteriophages, broadly defined as 
viruses that infect bacteria, their origin is hypothesized to occur soon after the advent of 
the first prokaryotic cells on Earth over three billion years ago (Hendrix, et al. 1999; 
Pedulla, et al. 2003). The similarities between structural and replication proteins among 
viruses that infect the three different domains of life suggest that viruses may be older 
than the Last Universal Common Ancestor (LUCA) (Forterre 2006). Beyond just existing 
(and likely infecting) the LUCA, it has been suggested that viruses drove the 
differentiation among the three domains of life (one hypothesized mechanism suggests 
DNA viruses fused with RNA cells to create DNA cells from a RNA-celled LUCA) 
(Forterre 2006). Of the modern-day viruses that infect the three domains of life, 
bacteriophages are by far the most abundant group. It is estimated that there are over 
1031 bacteriophages on Earth, with 1025 infections estimated to occur every second, 
making bacteriophages the most abundant biological entities on Earth (Pedulla, et al. 
2003).  
Bacteriophages were first discovered in 1915, when British pathologist Fredrick 
Twort described a filter-passing virus which could turn a micrococci streak “glassy” and 
was also able to infect Staphylococcus aureus without action on E. coli cells (Twort 
2011). Twort did not follow up with his discovery, informing readers at the end of his 
Lancet article with the line “I regret that my financial considerations have prevented my 
carrying these researches to a definite conclusion, but I have indicated the lines along 
which others more fortunately situated can proceed” (Twort 2011).  
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Two years later and independently of Twort, French-Canadian microbiologist 
Felix d‟Herrelle isolated invisible microbes which lysed Shigella cultures from the stools 
(and in one case, urine) of patients recovering from dysentery (D'Herelle 2007). 
Interestingly, d‟Harrelle was able to isolate these invisible microbes from only patients in 
the midst of recovery from dysentery rather than healthy individuals or those with 
dysentery who had not recovered (D'Herelle 2007). This led d‟Harrelle to conclude that 
“an antagonistic microorganism” was acting against the Shigella infection (D'Herelle 
2007). These “antagonistic micoorganisms” he named “bacteriophages”, which literally 
means “bacteria eater”. Unlike Twort, d‟Herrelle was financially able to continue work 
studying these new and mysterious microbes. D‟Herelle, even in that first 1915 paper, 
realized that bacteriophages could be used therapeutically. He proceeded to carry out a 
rabbit study in which these bacteriophages were successfully protective against Shigella 
and later used bacteriophages to treat humans, a treatment which in general has become 
known as bacteriophage therapy (Salmond and Fineran 2015).  
This bacteriophage therapy was similar in effect but mechanistically different than 
the anti-bacterial therapeutics first pioneered by German immunologist Paul Ehrlich 
(Bosch and Rosich 2008). Erchlich‟s creation, Salvarsan, was not just the first 
antimicrobial chemotherapeutic agent but also was so successful and widely acclaimed 
that Warner Brothers produced a 1940 movie titled Dr. Ehrlich‟s Magic Bullet in 
exaltation of his work (Bosch and Rosich 2008). D‟Herelle‟s ultimate success with 
bacteriophage therapy was much more limited than that of Ehrlich‟s creation of 
antimicrobial chemotherapeutic drugs. After d‟Herelle‟s early successes, such as treating 
patients with phage against plague, various pharmaceutical companies began selling 
phage preparations during the 1920s and 1930s to target a number of bacterial infections 
(Salmond and Fineran 2015).  
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Bacteriophage therapy spread with mixed results and was subsequently called into 
question, eventually falling under investigation by the American Medical Association in 
1934 (Summers 2001). The AMA concluded that the success of phage therapy was 
ambiguous and expressed concerns regarding the lack of criteria for purity of the phage 
mixture, the lack of standardization of phage preparations, and the lack of general 
understanding of how bacteriophage therapy worked (Summers 2001). Indeed, critics of 
D‟Herelle questioned whether his invisible microbes were viruses in the first place; 
rather, suggesting that they were enzymes (Keen 2012; Summers 2001). These doubts, 
combined with the outbreak of World War II (which D‟Herelle spent under house-arrest 
in Vichy, France) and the widespread adoption of antibiotics, doomed the further 
adoption and spread of bacteriophage therapy in the United States (Summers 2001). 
Bacteriophage therapy would, however, continue to be used by the Soviet Union and has 
been continuously studied in Eastern Europe up to the present day (Housby and Mann 
2009; Summers 2001).   
It was only later, in 1940, when Helmut Ruska, together with his brother Ernst 
Ruska, imaged a bacteriophage using their recently created technique of electron 
microscopy, that the debate concerning the viral nature of the bacteriophage phenomenon 
was settled (Kruger, et al. 2000; Salmond and Fineran 2015). In 1967, the International 
Committee for Taxonomy of Viruses (the ICTV) was founded in order to use information 
such as phage shape gained from techniques such as electron microscopy to classify 
bacteriophages (Adams, et al. 2017). In addition to morphology (enveloped/non-
enveloped, tail-shape) the ICTV has used nucleic acid type (ssDNA, dsDNA, ssRNA, or 
dsRNA) as well as genome organization (circular, linear, or segmented) to classify 
bacteriophages into 10 families within one Order (Caudovirales) (Ackermann 2003; 
Krupovic, et al. 2011). Bacteriophage genomes range in size from the 3.5kB ssRNA 
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genome of the levivirus GA to the 497.5kB dsDNA genome of myovirus G (Krupovic, et 
al. 2011). Over 5,000 individual phages have been isolated yet only 750 have been 
sequenced as of 2011 (Hatfull and Hendrix 2011). 70% of these sequenced genomes 
infect only 12 different bacterial hosts (Hatfull and Hendrix 2011). This dearth of 
information is especially striking in consideration of the estimate that there are over 100 
million phage species worldwide encoding for an estimated 2.5 billion ORFs (Rohwer 
2003).  
 
How Bacteriophages helped define Molecular Biology  
Little did the classical biologists, biochemists, immunologists, and physicists of 
the 1930s know that advances in bacteriophage research in the next two decades would 
help spawn the creation of a new paradigm of inquiry now recognized as molecular 
biology. In 1935, while the burgeoning prospect of bacteriophage therapy began fading in 
the West, the utility of bacteriophages was just beginning. In that year, German 
theoretical physicist Max Delbrück, together with Soviet biologist Timofeev-Ressovsky 
and German biophysicist K.G. Zimmer, would publish a paper that was a result of their 
working group on how physics can be applied to biology in order to understand the 
nature of the gene (Summers 1993). Their conclusion, based in part on the work by the 
University of Texas professor H. J. Muller that ionizing radiation caused mutations in 
flies, was that genes had to have “a kind of stability similar to that of molecules” 
(Delbruck 1970). While this notion of the physical nature to the structure and function of 
the gene seems trivial by modern standards, at the time it and most other elements of 
molecular biology were thoroughly unexplained.   
Based on this work Delbrück was invited to Caltech in 1937 on a fellowship 
(Delbruck 1970). Soon after arriving there he met post-doctoral research fellow Emory 
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Ellis, who introduced Delbrück to bacteriophages (Summers 1993). Ellis, funded through 
the generosity of wealthy mining industrialist Seeley Wintersmith Mudd to study viral 
carcingogenesis, decided that a more fundamental understanding of viral infection was 
first necessary (Summers 1993). The relative ease of manipulation and speed of life cycle 
attracted Ellis to bacteriophages, even though the viral nature of bacteriophage was an 
open debate and, at the time, was an idea held by a minority of researchers (Summers 
1993). In Ellis and bacteriophages, Delbrück, who was educated as a theoretical physicist 
under Niels Bohr and had developed a deep interest in solving “the riddle of life”, saw an 
opportunity to develop a “deeper understanding of this process through a quantitative 
experimental approach” (Delbruck 1970). To Delbrück, phages were the easiest system 
by which he would be able to interrogate the nature of the gene and its function in life. 
Ellis and Delbrück published their first and only paper together in 1939 describing one-
step growth experiments using an E. coli infecting bacteriophage (Ellis and Delbruck 
1939). In that paper, they developed key ideas that would later become standardized 
throughout phage biology such as the plaque assay, absorption, latent period, and viral 
burst size (Ellis and Delbruck 1939; Salmond and Fineran 2015).    
While funding constraints moved Ellis back to cancer research, Delbrück 
continued on studying bacteriophages (Summers 1993). Delbrück would publish two 
papers independently on the role of various growth conditions on phage absorption and 
on the nature of cell lysis (Delbruck 1940a, b). In 1940, at the end of his fellowship at 
Caltech, Delbrück would move to Vanderbilt University where he would teach in the 
physics department until 1947 (Cairns 2007). It was there that Delbrück and Italian 
microbiologist Salvador Luria would perform the experiments studying the nature of 
bacteriophage resistance that they would later be awarded a Nobel Prize (Luria and 
Delbruck 1943; Salmond and Fineran 2015).  
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Delbrück and Luria had noticed that there would be secondary growth hours after 
initial phage lysis of a liquid bacterial culture. These bacterial cells that made up the 
secondary growth step were resistant specifically to the phage used to cause the initial 
lysis. Delbrück and Luria realized that these phage-resistant bacterial cells could have 
become resistant in two different and mutually exclusive ways: that the cells were already 
resistant to the phage before exposure (the mutation hypothesis) or that the cells acquired 
immunity to the phage after exposure (the acquired immunity hypothesis). They 
developed a theoretical and mathematical framework from which they were able to 
develop experimental tests using T1 bacteriophage and E. coli B cells to determine which 
of the two hypotheses was correct (Luria and Delbruck 1943). Their experiments showed 
that when replicate bacterial cultures, all started from the same original culture, are 
independently exposed to phage, the resultant counts of resistant cells had a high 
variance. This confirmed the mutational hypothesis because the acquired hypothesis 
presupposes a less varied number of resistant cell counts. Their experiment was the first 
to show that mutations arise independently of selection pressure and, as Luria later put it 
“attracted attention to the remarkable possibilities of bacterial genetics” (Cairns 2007). 
The pioneering work by Delbrück and Luria had indeed drawn the attention of 
many others. In 1945, Delbrück and Luria, together with Alfred Hershey, set up the first 
of twenty-six annual summer Phage courses at the Cold Springs Harbor Laboratory 
(Cairns 2007). This class was the impetus for the creation of the so-called “Phage Group” 
which consisted of those interested in bacterial and phage genetics. In addition to 
providing the environment to facilitate the exchange of results and ideas the Phage 
courses also allowed Delbrück by edict to codify which phages, host strains, and 
techniques were supposed to be used by those in the group (Cairns 2007). This 
standardization led to the “T” nomenclature (“T” for “type”) used now for T1 through T7 
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phages based on the first electron micrographs of E. coli infecting phages published in 
1943 (Cairns 2007; Luria, et al. 1943).    
The 1946 Symposium opened up to much fanfare regarding Edward Tatum and 
George Beadle‟s one-gene-one-enzyme hypothesis. In their seminal 1941 paper, they 
noticed that X-ray irradiated Neurospora crassa (common bread mold) would commonly 
lose the ability to grow in the absence of a single metabolite. They were able to isolate 
different strains, each of which would not grow in the absence of their respective 
metabolite while still being able to grow on media lacking another metabolite (Beadle 
and Tatum 1941). This data led them to conclude that one gene produced one enzyme 
responsible for a single step in a metabolic pathway. This and other auxotrophic data 
presented in support of the one-gene-one-enzyme hypothesis was challenged by 
Delbrück, who argued that no current series of experiments at the time could be devised 
to disprove the hypothesis (Cairns 2007). As a result, Norman Horowitz realized he could 
use temperature-sensitive mutations to lend support to the one-gene-one-protein 
hypothesis and thus the meeting spurred the development the powerful innovation of the 
use of temperature-sensitive mutants in bacterial genetics (Cairns 2007). For their 
discovery, Beadle and Tatum would be awarded half of the 1958 Nobel Prize in 
Physiology or Medicine (Norrby 2008).     
It was at the 1946 Cold Springs Harbor Phage Symposium that Joshua Lederberg 
and Edward Tatum announced their discovery of genetic recombination via sexual 
reproduction in E. coli, which later would be shown to be because of bacterial 
conjugation (Lederberg and Tatum 1946; Tatum and Lederberg 1947). In their 
experiment, they noticed that two different triple auxotrophic E. coli cell lines (the first a 
threonine, leucine, and thiamine auxotroph and the second a biotin, phenylalanine, and 
cysteine auxotroph) which would not grow if plated individually would indeed grow after 
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being in physical contact for a time with one another and then subsequently grown in a 
culture without all six nutrients (thus becoming prototrophic) (Tatum and Lederberg 
1947). This work confirmed bacterial recombination in the form of conjugation and 
would be the basis for Lederberg and Tatum sharing half of the 1958 Nobel Prize 
(Norrby 2008).  Recombination in bacteriophages had been shown earlier that year when 
Albert Hershey had used T2 phages with two independent mutations (one for 
clear/cloudy plaques and the other host-range dependence) to show that multiple 
infections in the same cell could occur with the result that phages also could experience 
recombination (Hershey 1946). Not to be outdone, Delbrück in the same year had 
independently discovered phage recombination (Cairns 2007; Delbrück and Bailey 1946).      
  Incredibly, this work was done before it became widely accepted that DNA was 
the genetic material of living things. In 1944, biochemists (and decidedly non-Phage 
Group members) Oswald Avery, Colin MacLeod, and Maclyn McCarty published their 
data continuing their work on a system where a live but non-pathogenic R strain of 
pneumococcus, when injected into mice with a large amount of heat-killed pathogenic S 
strain of pneumococcus, would lead to lethality to the mice in which blood was generated 
live and pathogenic R strain of pneumococcus (presumably through transformation of the 
R strain with a factor that made them pathogenic from the S strain) (Avery, et al. 1944). 
With this exciting model of cellular transformation, in the 1944 paper, the Rockefeller 
Institute trio would take these results one step further and show that only when the live 
but non-pathogenic strain of R strain pneumococcus was transformed in-vitro with the 
DNA component of the heat-killed pathogenic S strain pneumococcus (versus the RNA 
or protein component) did the subsequent cells become virulent and lethal to mice 
(Avery, et al. 1944).  
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While this paper “strongly suggest[ed] that nucleic acids, at least those of the 
desoxyribose [sic] type, possess different specificities as evidenced by the selective 
action of the transforming principle” the conclusive evidence that genes were made of 
DNA was not found until 1952. In that year Albert Hershey and his lab assistant Martha 
Chase would publish their results in which they separately used S35 and P32 isotopes to 
radiolabel the protein and the nucleic acid, respectively, of T2 phage (Hershey and Chase 
1952). These either protein or nucleic acid-tagged T2 phages were then used to infect 
unlabeled E. coli cells. After initial phage absorption, they blended off the T2 phage 
capsids from the now infected E. coli cells which were collected via centrifugation. These 
E. coli cells were then lysed which led to detection of P32 but not S35 in the slurry. 
These data showed that the T2 DNA was initially protected by a protein capsid which 
then entered into the E. coli cells. Hershey and Chase correctly concluded that this means 
that genes were made out of DNA, not protein. Hershey (but not his lab assistant Martha 
Chase) would share the 1969 Nobel Prize with Luria and Delbrück for “their discoveries 
concerning the replication mechanism and the genetic structure of viruses”.    
In April 1953 James Watson and Francis Crick would publish the structure of 
DNA (Watson and Crick 1953).  For their work, heavily influenced by the crystal 
structures generated by Rosalind Franklin and Maurice Wilkins at the Cavendish 
Laboratory, they would later win the 1962 Nobel Prize, notably with Wilkins and without 
Franklin who had passed away (Maddox 2003). While Watson is known by many for the 
discovery of the structure of DNA he is less known for his initial work within the Phage 
Group. Watson went to Indiana University for his graduate work to study under Salvador 
Luria (Cairns 2007). While there, he worked with Renato Dulbecco on the properties of 
T2 bacteriophage inactivated with X-rays (Watson 1950). It was at the urging of 
Delbrück and Luria that Watson would go to work on the structure of DNA at the 
 10 
Cavendish Laboratory at University of Cambridge (Cairns 2007). While Watson‟s 
subsequent work was decidedly non-phage related it is worth noting that in 2004 as the 
Director of Cold Springs Harbor Laboratory he co-authored a Nature Biotechnology 
correspondence in opposition of a News and Views piece in which he defended the future 
prospects of phage therapy (Schoolnik, et al. 2004).      
Phage Group member Gunter Stent would later observe that “unlike the discovery 
of the alpha-helix [by Linus Pauling et al. in 1951], the discovery of the DNA double 
helix opened up enormous vistas to the imagination. It provided highroad to 
understanding how the genetic material functions.” (Cairns 2007; Pauling, et al. 1951). 
Even in their seminal Nature paper Watson and Crick speculated that “[i]t has no escaped 
our notice that specific pairing we have postulated immediately suggests a possible 
copying mechanism for the genetic material” (Watson and Crick 1953). In 1958 Matthew 
Meselson and Franklin Stahl would publish their results on DNA replication in E. coli 
using N14 and N15 containing media to show the semi-conservative nature of DNA 
(Meselson and Stahl 1958). In a five year span from 1961-1966 the work of many 
researchers, initially using cell-free protein synthesis using randomly ordered RNA and 
later deciphering the RNA codons via determining ribosomal-bound aminoacyl-tRNAs, 
quickly established the nature of the genetic code, transcription, and translation 
(Nirenberg 2004).  
The rapid development of molecular biology, only a fraction of which is actually 
cited here, led from the discovery of the structure of the double helix in 1953 to Crick‟s 
1970 Nature paper clarifying and codifying the known mechanisms of information flow 
through the various biological components now known as the “Central Dogma of 
Molecular Biology” (Crick 1970).    
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Interestingly, these later discoveries that fleshed out the structural basis of the 
Central Dogma were admittedly not made by those in the Phage Group. Rather, they were 
made by those that would call themselves physicists or biochemists.  Those who have 
written about the Phage Group note that Delbrück had a dislike for biochemists, stated in 
a 1949 lecture that, a physicist: 
 
Listening to the story of modern biochemistry he might become persuaded that 
the cell is a sack full of enzymes acting on the substrates converting them through various 
intermediate stages either into cell substance or into waste products…The enzymes must 
be situated in their proper strategic positions to perform their duties in a well-regulated 
fashion. They in turn must be synthesized and must be brought into position by 
maneuvers which are yet understood, but which, at first sight at least, do not necessarily 
seem to differ in nature from the rest of biochemistry…And yet this program of 
explaining the simple through the complex smacks suspiciously of the program of 
explaining atoms in terms of complex mechanical models. It looks sane until paradoxes 
crop up and come into sharper focus, and this will not happen until the behavior of living 
cells has been carried into far greater detail. This analysis should be done on the cell‟s 
own terms and theories should be formulated with fear of contradicting molecular 
physics. I believe that it is in this direction that physicists will show the greatest zeal and 
will create a new intellectual approach to biology which would lend meaning to the ill-
used term biophysics. (Cairns 2007) 
Delbrück certainly helped pioneer this “new intellectual approach to biology” 
which we now call molecular biology, and certainly used bacteriophages as his chariot. 
Ultimately though, the aforementioned transition occurred between those fundamental 
discoveries from the Phage Group to those by the (Delbrück-maligned) biochemists after 
the discovery of the structure of DNA. This can be explained in almost philosophical 
terms as a differing of mindset between the information-driven Phage Group and the 
structurally-driven biochemists (Cairns 2007). Delbrück‟s initial interest in biology stems 
from some hope articulated by Bohr that the complexity of life could be born out through 
the discovery of some sort of rules, or “complementary principles”, of physics that were 
yet theretofore unrecognized (Cairns 2007).  
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Of this so-called “Copenhagen Spirit” which developed out of Bohr‟s thoughts 
about physics and motivated Delbrück and others, Stent writes, “it was the Copanhagen 
Spirit that provided the philosophical infrastructure for navigating latter-day biological 
thought between the Scylla of crude biochemical reductionism, inspired by 19th century 
physics, and the Charybdis of obscurantist vitalism, inspired by 19th century 
romanticism” (Cairns 2007). In many ways this paradox vis-à-vis reductionism and 
holism which was so motivating during that time period is reflected in the present as the 
creative dichotomy between pure physical reductionism and the study of biological 
consciousness (or even the most recent effort to interpret emergent biological phenomena 
using systems biology).  
 
Discovery and Uses of Bacteriophage T7 
In 1970, with the establishment of the Central Dogma, the field of molecular 
biology had been firmed defined and began to be used as a basis of inquiry into the 
manifold phenomena of life. This inquiry included continued work into learning about 
bacteriophages. Though far from being the central driver into advancing the field as it 
had before, work on bacteriophages was far from over with even as those in the Phage 
Group hung up their mouth pipettes. The benefits of studying bacteriophage, namely, 
their relative speed, ease, and low-cost, still held true. The early standardization of which 
phages to study among the Phage Group by Delbrück resulted in its own frozen accident 
by which the T-phages became the preferred and even dominant bacteriophages as 
subjects of research. Because the subject matter of this thesis is the bacteriophage T7, it is 
worthwhile to describe a bit about its origins and utility.          
There are a few pieces of evidence that relate to the discovery of bacteriophage 
T7. According to molecular biologist and historian W.C. Summers (via personal 
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communication with Max Delbrück), T7 was discovered when Delbrück isolated only 
one kind of phage from a commercial laboratory that he was visiting that was advertising 
a polyvalent phage mixture for bacteriophage therapy (Summers 2001).  T7 first occurs in 
the literature in a 1944 paper by Demerec and Fano in which they say that T7 was 
“isolated from the standard anti-coli-phage mixture prepared by Dr. W. J. MacNeal” who 
they would later in their acknowledgements mention was “of the New York Post-
Graduate Medical School and Hospital” (Demerec and Fano 1945). Whether this anti-
coli-phage mixture was actually created by Dr. MacNeal or originated from a commercial 
mixture used by him created by a company (maybe even the same one Delbrück visited) 
has been lost to time.  
Regardless of its origin, bacteriophage T7 became a useful tool for studying DNA 
replication and RNA transcription (Calendar 2006). Incredibly, eight of the 55 proteins 
coded for in the T7 genome have been well-characterized enough and have enough 
interesting functionality to currently be available commercially: its DNA polymerase, 
RNA polymerase, lysozyme, exonuclease, endonuclease I, Ocr protein, DNA ligase, and 
helicase. The T7 DNA polymerase, together with the E. coli thioredoxin protein, has 
DNA polymerase activity with high fidelity at a rapid rate and with 3‟ to 5‟ exonuclease 
activity and is sold as purified protein by New England Biolabs for second strand 
synthesis in site-directed mutagenesis protocols (Biolabs 2017c). The T7 RNA 
polymerase is a DNA-dependent RNA polymerase with high in-vitro activity and 
specificity for its own T7 promoter and is sold as purified protein by New England 
Biolabs for RNA synthesis (Biolabs 2017f). The T7 lysozyme has the ability to inhibit 
the RNA polymerase and is sold on an inducible plasmid by New England Biolabs as part 
of E. coli protein expression systems (Biolabs 2017a). The T7 exonuclease, working in 
the 5‟ to 3‟ direction, removes mononucleotides from both phosphyrolated and 
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unphosphorylated duplex DNA and is sold as a purified protein by New England Biolabs 
for molecular cloning purposes (Biolabs 2017e). The T7 endonuclease I recognizes non-
perfectly matched DNA and Holliday junctions and is sold as a purified protein by New 
England Biolabs for DNA  repair and genome editing detection (Biolabs 2017d). The T7 
Ocr protein mimics the structure of B-DNA such that it binds to and inhibits type I 
restriction-modification systems and is sold as a purified protein by Lucigen as an 
additive to increase transposon efficiency in bacterial cells (Lucigen 2017). The T7 DNA 
ligase catalyzes the formation of 5‟ to 3‟ phosphodiester bonds without acting on blunt 
end ends and is sold as a purified protein for molecular cloning purposes (Biolabs 
2017b). Finally, the T7 helicase has highly processive 5‟ to 3‟ helicase activity together 
with primase activity and is sold commercially as a purified protein by Biohelix  for 
isothermal DNA amplification techniques (Biohelix 2017). 
 Far from being plundered to model DNA replication and RNA polymerization (or 
other pieces for later commercialization and utility), bacteriophage T7 continued to be the 
subject of investigation into its life-cycle and evolution. The genetic mapping of T7 was 
first published in part in 1969 and in full in 1972 (the complete sequence was first 
published in 1983) (Calendar 2006; Dunn and Studier 1983; Studier 1972, 1969). With a 
genetic map (and, later complete genome) in hand at such a relatively early time in the 
progression of molecular biology, bacteriophage T7 stood out as a model system for 
experimental evolution. While not attempting to be exhaustive, it is worth mentioning a 
few of the bacteriophage T7-based experimental evolution systems to illustrate its 
versatility.  
It was noticed bacteriophage T7 could tolerate an accelerated mutation rate 
through the use of growing and lysing E. coli cells grown in the highly mutagenic 
chemical N-methyl-N‟-nitro-N-nitrosoguianidine (NNNG). Indeed, later, in an effort to 
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use NNNG to reach lethal mutagenesis in bacteriophage T7 populations, the phage 
tolerated an astounding 245 mutations per genome over 200 generations yet failed to 
become extinct (Springman, et al. 2010). Earlier, however, an experiment was designed 
in which NNNG would induce mutations subsequently detected with various restriction 
enzyme digests (Bull 1993). This increased mutation rate enabled the creation of the first 
known experimentally-derived phylogeny from which the previous a prori-based 
phylogenetic algorithms could be checked, verified, and compared to one another, with 
one method in particular found to be greater than 98% accurate (Hillis, et al. 1992). This 
work, for the first time, directly supported the phylogenetic methods which were and still 
are being used to estimate branching points, branch lengths, and ancestral genotypes 
(Hillis, et al. 1992). The same protocol was extended to show the effect of parallel 
molecular evolution of deletions and nonsense mutations with regards to phylogenetic 
analyses (Cunningham, et al. 1997). 
Through various complementation experiments between bacteriophages and 
plasmids it was discovered that that bacteriophage T7 could recombine with plasmids, 
and in so doing provided an important tool by which to study gene variants and gene 
placement in the context of the bacteriophage (Campbell, et al. 1978). This technique 
allowed a bacteriophage T7 mutant to be created without its own RNA polymerase which 
was subsequently passaged on the related bacteriophage T3 RNA polymerase in order to 
study the regulatory evolution and effect on overall fitness of T7 (Bull, et al. 2007). In 
this study, the 9 of 16 promoters picked up the single mutation which conferred high 
activity on the T3 RNAP. Regulatory evolution using the T7 RNA polymerase was 
interrogated in a different way by recombining it back in at various locations throughout 
the bacteriophage T7 genome in order to investigate gene order (Springman, et al. 2005). 
Two of these lines picked up enabling mutations in the T7 terminator while one resulted 
 16 
in a recombination of the T7 RNA polymerase back closer it‟s wild-type location early in 
the genome. Other bacteriophage T7 adaption experiments have been done on deletions 
of a key DNA metabolism gene (its DNA ligase) as well as in response to a T7 promoter-
driven, plasmid-based, suicide circuit (Bull and Molineux 2008).  
Other bacteriophage T7 experimental evolution experiments have continued on in 
this tradition by attempting to rationally design or expand the genetic code. One group, 
inspired by rational design and engineering principles, refactored the leftmost 11,515 
base pairs of the 40kB genome in order to remove overlapping genes, remove unwanted 
restriction sites, and add desirous restriction sites (Chan, et al. 2005). Subsequent 
passaging of the refactored bacteriophage T7 kept 60-70% of the added design elements 
(Springman, et al. 2012). Another example of rational design, in this case, for the explicit 
purpose of viral attenuation, was the codon-modification of the gene 10, which codes for 
the major capsid protein (Bull, et al. 2012). Four versions of the gene 10, all coding for 
the same amino acid content of the wild-type major capsid protein, were constructed with 
decreasing fraction of preferred codons (wild-type: 68% preferred codons, variants: 50%, 
30%, 20%, and 10% preferred codons). These were then recombined into T7Δ10 
bacteriophage (phage lacking the gene 10) and passaged. Overall fitness initially 
decreased linearly with decreased preferred codon content. Interestingly, the 10% 
preferred codon variant did regain fitness, however, at a very slow rate, suggesting that 
codon de-optimization, at least in this proof-of-concept bacteriophage T7 model, was a 
viable strategy for short-term viral attenuation.  
Finally, one of the most recent examples of bacteriophage T7 experimental 
evolution is the discovery that it will use an expanded genetic code in order to proceed 
toward evolutionarily higher fitness (Hammerling, et al. 2014). Bacteriophage T7 was 
passed in an E. coli strain which had an orthogonal tRNA and aminoacyl-tRNA-
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synthetase pair to provide 3-iodotyrosine at amber codons. After 50 transfers, one of the 
phage populations was sequenced and it was discovered that 55% of that mutator strain 
population (which used an error-prone T7 DNA polymerase to stimulate mutations) had 
an amber mutation in the T7 holin gene. They found that the amber-containing phages 
were able to out-compete spontaneous rescue mutants at the same position in co-culture 
experiments in the same experimental conditions. This is one of a multitude of examples 
of how bacteriophage T7, far from being fully understood and described, has aided and 
will continue to aid in investigating intriguing evolutionary questions. 
It is also worth mentioning here that bacteriophage T7 has been used for phage 
display. Phage display is a selection technique by which phage phenotype, the display of 
a protein or peptide on the phage capsid surface, is linked to its genotype, which is 
encapsulated in the phage. The phages, containing the DNA coding for the peptide or 
protein variants on their surface, are then subjected to in-vitro binding or “panning” 
whereas a particular target of choice (a small-molecule, nucleic acid, peptide, or protein) 
is tethered to a surface on which the phages are added and then washed away. Those 
variants that successfully bind are isolated and enriched while those that do not bind are 
washed away and lost. Those high-affinity variants are then assayed for desired activity. 
While there display systems based on many phages, including, filamentous/M13 phages, 
T4 phage, and lambda phage, the advantages of the T7 phage display system are: 1) the 
systems high tolerance for an extreme chemical environment, 2) the capsid is not 
involved with phage absorption thus the peptide/protein of interest should not alter 
infection and 3) it is not necessary to secrete the displayed peptides/proteins through the 
periplasm and cell membrane (which ultimately does limit the inclusion of post-
translational modifications) (Bazan, et al. 2012). Together, phage display is a highly 
versatile and useful technology to discovering as well as increasing the affinity of 
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peptide/protein-small-molecule, peptide/protein-peptide/protein, and peptide/protein-
nucleic-acid interactions of which bacteriophage T7 is one tool in the toolbox.                   
 
Transition from Understanding to Engineering of Biology 
From Crick‟s clear articulation of the Central Dogma in 1970 until the current day 
the pendulum of research has swung from efforts to purely understand biology (what 
could be called “basic research”) to those efforts to engineer biology (what could be 
called “applied research”). The panoply of nucleic acids, proteins, and biologically 
relevant chemistries among the diversity of life on Earth has provided a rich starting point 
for the development of applied tools and techniques. These tools and techniques 
developed from the applied research standpoint can be and often are used cyclically to 
further enable the exploration and discovery of additional basic research. Of course, 
bacteriophages, directly or indirectly, have had a role in the shaping of these tools and 
techniques. A few of the key discoveries and bacteriophage tie-ins are noted here.   
Sequencing 
The ability to actually discern the exact order of nucleotides in DNA or RNA as 
well as amino acids in proteins, collectively known as sequencing, was one of the 
fundamental advancements in applied research which helped bring about the era of 
engineering biology. Though this sequencing, or “reading” of the DNA, RNA, and 
proteins, was initially promoted by the establishment of the genetic code the ability, to do 
so readily (or, more so, inexpensively) took time and technological development. The 
first nucleic acid ever sequenced was the S. cerevisiae alanine tRNA in 1965 (Heather 
and Chain 2016). Closely following this development was the sequence of the first 
protein-coding sequence and genome, that of the bacteriophage MS2 coat protein and 
later its full 3,959 nucleotide ssRNA genome, in 1972 and 1976, respectively (Fiers, et al. 
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1976; Heather and Chain 2016; Salmond and Fineran 2015). While these early successes 
in RNA sequencing were based upon using radiolabeled partial-digestion and 2D 
fractionation, it was not until Fred Sanger developed chain-termination sequencing that 
the first DNA genomes were sequenced (Heather and Chain 2016). This chain-
termination sequencing used radiolabeled ddNTPs incorporated into the 3‟ ends of DNA 
pieces by DNA polymerases. Four of these incorporation reactions (one for each ddNTP) 
would then be resolved in each of four lanes using polyacrylamide electrophoresis. Using 
this technique, Sanger was able to sequence the first DNA genome: that of the 5,375 base 
pair dsDNA bacteriophage ΦX174 (Sanger, et al. 1977). 
Sanger‟s early methods would be further developed and modified (most 
importantly by moving to flourometric detection and scaling/multiplexing) to 
accommodate more complex genomes. This culminated in the completion of the Human 
Genome Project in 2001, in which bacteriophage-derived M13 vectors and T4 DNA 
ligase played crucial roles (Lander, et al. 2001; Salmond and Fineran 2015). It was 
around this time that the second-generation of sequencing technology (collectively 
known as next generation sequencing) was initially developed by 454 Life Sciences but, 
conceptually, extends to IonTorrent and Illumina sequencing technology (Heather and 
Chain 2016). In all of these methods, DNA becomes isolated in some way from each 
other (either by emulsion PCR or ligation to a surface), subsequently amplified using 
DNA polymerase, and then detected in a highly parallelized fashion. It is worth 
mentioning that a third generation of sequencing technology (still considered next 
generation sequencing) known as single-molecule sequencing. One example of  this 
technology, initially developed by the now-defunct Helicos Biosciences and now used by 
Pacific Biosciences, detects, in real-time, fluorescent nucleotides as they are incorporated 
into the nascent polymerization product by DNA polymerase (Heather and Chain 2016). 
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This uniquely enables PacBio to create incredibly long reads. Another example of a 
single-molecule sequencing technology is the use of nanopores such that the newly 
polymerized DNA product gets threated through a pore in a synthetic membrane which is 
able to detect specific nucleotides by the application and detection of voltage (Heather 
and Chain 2016). These next-generation sequencing technologies, broadly enabling for 
DNA sequencing, are also used for RNA sequencing: all that is necessary has been to 
take an extra step by which RNA transcripts of interest are converted into cDNA by a 
reverse-transcriptase step (Ozsolak and Milos 2011). These technologies have led to 
widespread ease of sequencing genomes: currently, there are over 7000 viral, 100,000 
prokaryotic, and 4500 eukaryotic genomes in the NCBI genome database (NCBI 2017).    
Protein sequencing, in relation to RNA or DNA sequencing, has been historically 
and is presently more difficult on account of more variation of substituents (four standard 
nucleotides versus twenty standard amino acids), lack of selective amplification (there is 
no protein equivalent to PCR), and heterogeneity among various proteins made inside of 
a cell (which, though an issue, can be overcome by selective tagging and purification 
techniques). Initial work into protein sequencing focused on a technique developed by 
Peer Edman where chemical cleavage of the amino terminus of a protein is used to 
identify each amino acid in a step-wise manner (Steen and Mann 2004). This burdensome 
technique wound up being largely displaced by protein mass spectrometry, in which 
proteins are cleaved, ionized, and have their masses are measured relative to their 
displacement in a vacuum (Steen and Mann 2004). Though protein mass spectrometry 
has become the current state-of-the-art, with various techniques able to pick up on single 
amino acid substitutions, isotope shifts, and protein modifications, there is some hope 
that future developments will lead to single-molecule labeling or nanopore-esque-based 
protein sequencing.  
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Synthesis 
Paralleling the increasing capability for sequencing or “reading” of biological 
material has been efforts towards synthesis, or, by analogy, “writing” these DNA, RNA, 
and proteins. The first synthetic gene ever built was the 77 base-pair tRNA in 1940 
(Hughes, et al. 2011). De novo DNA synthesis using phosphoramidite chemistry 
progressed into the 1950s and can be noted for being error-prone and limited in length 
(Kosuri and Church 2014). While the same basic phosphoramidite chemistry has 
persisted as the state-of-the-art, major advancements have occurred: multiplexing, 
ligation-supplemented synthesizing, and error-correcting protocols have enabled the 
reliable construction of larger and larger assemblies up to the gene level (Hughes, et al. 
2011; Kosuri and Church 2014). These advancements have facilitated the complete 
chemical syntheses of multiple genomes, including the first fully synthetic genome, that 
of bacteriophage ΦX174 in 2003 (which, fittingly, and noted previously, was the first 
whole genome sequenced) (Hughes, et al. 2011; Salmond and Fineran 2015). While costs 
and time requirements have decreased (a gBlock from IDT currently cost run from $89 
USD for 125-250 base pairs up to $549 USD for 2751-3000 base pairs in a few weeks 
while the original 77 nucleotide tRNA, though cost unknown, required five years of 
work) they have not decreased at the same rate as sequencing costs (Hughes, et al. 2011; 
Integrated DNA Technologies 2017).  
RNA synthesis is almost always done in-vitro or in-vivo (rather than by chemical 
synthesis) using DNA as its template and enzymes such as the T7 RNA polymerase. 
While chemical protein synthesis of peptides is routine, the creation of larger 
polypeptides on the protein-scale are almost always also created in-vivo or in-vitro.  
Copy, Cut/Pasting, and Editing 
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As the development of sequencing and synthesis progressed, others were 
discovering or developing the technology for being able to copy, cut/paste, and edit DNA 
(which, by proxy, also includes RNA and proteins). The ability to directly copy DNA via 
polymerase chain reaction, though routine and instrumental after, only matured in the 
mid-1980s as a the product of work by many over the previous 20 years (Bartlett and 
Stirling 2003). Until then, it took another set of tools to allow the creation of transgenic 
constructs and novel gene circuits. The existence of bacteriophages (or, more specifically, 
prokaryotic defense mechanisms in which to defend against them) led to the development 
of this suite of tools which have been critical in the development of this cut/paste (and, 
later editing) technology.  
The discovery of restriction-modification systems, which are hypothesized to 
have evolved in prokaryotes for the purpose of protecting the cell against foreign DNA a 
la bacteriophages, is one example of a discovery in basic research which ultimately drives 
technology in the use of restriction enzymes (Salmond and Fineran 2015). Until the more 
novel forms of DNA cloning in the last decade or so, restriction enzymes and DNA 
ligases (also bacteriophage derived) were the only tools by which various pieces of 
discordant DNA could be stitched together to make novel transgenic constructs or genetic 
circuits. These key discoveries, together with PCR, enabled the burgeoning field of 
genetic engineering.  
Satisfyingly similar to the discovery and technological exploitation of restriction-
modification systems has been the discovery and technological exploitation of 
CRISPR/Cas systems. CRISPR systems, the arrays of which were first noticed in early 
prokaryotic sequencing as runs of small identical sequences interspersed by wildly 
different intervening sequences of roughly the same size, were eventually postulated and 
shown to provide sequence-specific immunity against bacteriophages in 2007 
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(Barrangou, et al. 2007; Salmond and Fineran 2015). Within five years, CRISPR/Cas 
systems, which enable sequence-specific, RNA guided nuclease activity towards DNA in 
almost all parts of the biological tree of life, would become widely adopted for their gene 
editing ability (Salmond and Fineran 2015). Rapid genome engineering by CRISPR/Cas 
systems, following on from zinc-finger nuclease and TALEs, has enabled development in 
basic research (animal models and genetic variation), biotechnology (fuel, food, and 
materials), and medicine (gene therapy and drug development) (Hsu, et al. 2014).         
One of the earliest and most widely adopted of the CRISPR/Cas9 systems was a 
type II CRISPR/Cas system which was chosen for its simplicity for adaption to 
biotechnological purposes:  one protein, Cas9, interacts with one RNA, the sgRNA , for 
full nuclease activity (Salmond and Fineran 2015). A nicking Cas9 has been created by 
inactivating one of the two nuclease domains while a nuclease deficient Cas9 has been 
created by inactivating both the nuclease domains (Qi, et al. 2013). The nuclease-
deficient Cas9 (which is often called dCas9) still retains DNA binding function and can 
act as a stand-alone repressor or an activator when fused to prokaryotic RNA polymerase 
subunits (Bikard, et al. 2013). Cas9 as well as dCas9 have been further used within the 
context of conjugative plasmids and phagemids with the explicit purpose of allowing 
selective gene targeting or gene modulation inside of prokaryotes (Bikard, et al. 2014; 
Citorik, et al. 2014). This work gives rise to the hope that such systems can be exploited 
to root out specific, antibiotic-resistant bacterial strains or modulate the medically 
relevant prokaryotic communities of the human microbiome. If so, this newest iteration 
of technology would truly represent the wheel turning full circle back to phage-based 
therapy.  
 
Molecular Methods to Engineer Bacteriophage 
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The ability to read and write nucleic acids (and therefore proteins) has further 
enabled modern methods to engineer and evolve bacteriophage genomes. The genomes of 
bacteriophages can be altered inside of cells through means of homologous 
recombination (as in the case of bacteriophage T7), in-vivo protein-directed 
recombination (as in the case of use of the lambda phage recombination machinery and 
electroporated homologous ssDNA or dsDNA), and even the use of the CRISPR/Cas9 
system (as has been shown for multiple phages, including the use of a type-I-E CRISPR-
Cas system to engineer bacteriophage T7) (Kiro, et al. 2014; Pires and Cleto 2016). 
Bacteriophage genomes can also be altered and engineered in-vitro. The previously 
mentioned creation of the refactored bacteriophage T7 utilizing particular engineering 
design strategies was done by the division of the T7 genome into three pieces on three 
plasmids which, when transformed into the same cell, led to successful phage production 
(Chan, et al. 2005). Another technique to engineer and evolve bacteriophages has used a 
cell-free transcription-translation system derived from E. coli cells in which 
bacteriophages T7 and ΦX174 have been shown to replicate and assemble into infective 
virons (Shin, et al. 2012). Finally, bacteriophage genomes can get around host toxicity 
problems associated with bacteriophage genome assembly by using assembly in a foreign 
and distantly related species, in this case, of bacteriophage T7 onto a plasmid in S. 
cerevisiae, which then can be prepped out of the yeast and used to transform E. coli in 
which the bacteriophage will begin life cycling (Ando, et al. 2015). 
These mostly modern methods of engineering bacteriophages have renewed 
interest in their therapeutic and biotechnological utility. In addition to previously 
mentioned use of bacteriophage as delivery-systems for effector Cas9/dCas9 systems, 
there are numerous examples of engineered bacteriophages that have been modified to 
deliver and overexpress a wide variety of antimicrobial proteins (Pires and Cleto 2016). 
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As but one example, lexA3, a protein which represses the SOS DNA repair system in E. 
coli, was overexpressed and delivered by an engineered M13 phage, thus enhancing the 
antibacterial activity of an exogenous antibiotic (Lu and Collins 2009). Additionally, 
these modern methods have been used to enable host range expansion of lytic 
bacteriophages via swapping of tail fibers (Ando, et al. 2015). Engineering efforts such as 
the work into decreasing the impact of engineered phages on mammalian systems 
(thereby decreasing immunogenicity) and the use of engineered non-lytic phages from 
wild-type lytic phages (thereby mitigating worry over LPS-based toxic shock from lysed 
bacterial cells) has sparked a renewed interest in the use of bacteriophage therapy (Barbu, 
et al. 2016; Pires and Cleto 2016). Beyond their therapeutic potential, engineered 
bacteriophages have been created for bacterial detection and diagnostic purposes (Pires 
and Cleto 2016). Finally, ability to conjugate or display various chemicals and proteins, 
such as antibiotics, peptides, and antibodies, on the surface of bacteriophages has led to 
their use as chassis for delivery of these materials in-vivo (Pires and Cleto 2016). 
Researchers have used bacteriophages in the field of materials science in unexpected 
ways, going as far as to fabricate cobalt-oxide nanowires from engineered M13 
bacteriophages for the purposes of increasing storage capacity in lithium ion batteries 
(Nam, et al. 2006; Pires and Cleto 2016). These increasingly complex and exotic uses of 
bacteriophages surely were unanticipated by those founding members of the Phage Group 
and represent bacteriophage‟s contribution to the modern manifestation of engineering 
and systematizing biology called synthetic biology. 
 
Synthetic Biology: the Latest Term for a Powerful Concept 
At the time of his death physicist Richard Feynman, whose foray into phage work 
during a sabbatical summer led to his inclusion on a paper in 1962, had on his blackboard 
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the statement “what I cannot create, I do not understand” (Edgar, et al. 1962). This 
statement expresses the ethos behind the relatively recent creation of so-called “synthetic 
biology”. The number of answers to the question what exactly is synthetic biology are 
likely as numerous as people asked. The history and coverage of synthetic biology can be 
found elsewhere in very excellent reviews and perspectives (Cameron, et al. 2014; 
Gardner and Hawkins 2013). The following is a brief attempt to extricate meaning from 
the term in order to understand the field as a whole and the motivation behind this thesis 
work.  
Synthetic biology is the newest title in a long line of titles such as genetic 
engineering, biotechnology, bioengineering, biodesign, and biological engineering which 
focus on one central concept: control. Synthetic biology is guided by innate human desire 
(and perhaps hubris) that believes matter can be and should be shaped in our desired way 
such that we can design the world around us to fit whatever specifications we want. This 
almost godlike ability to shape matter, in this case biological matter, is a guiding ideal far 
away from the reality of the situation. The reality is that we simply do not know enough 
about the various scales of biological phenomenon and how they interact with one 
another to reach this totality of control. We do, however, have to tools and technologies 
in place (including the few listed in the previous section) to increase our ability to read 
and write DNA, RNA, and proteins. Together with the inherited burden of human 
knowledge, this technology is being used for creation in order to test and increase our 
understanding of biological phenomenon. Synthetic biology is the attempt to do this.  
Synthetic biology uniquely stands out from the others in its stated desire for 
standardization. In a 1999 DARPA white paper, Adam Arkin and Drew Endy write that: 
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Without standardization, the qualitative design methods used in other engineering 
fields are simply inapplicable. [In practice, rational design of biological systems] is 
usually realized through an expensive step-wise trial and error approach or through 
mutation and selection. Furthermore, these otherwise practical approaches are limited in 
terms of problems they can solve. To address this deficiency, we propose herein a 
program to produce a set of well-characterized and systematized biological components 
that can be generically assembled to create custom biological circuitry. (Gardner and 
Hawkins 2013) 
This standardization of parts and of processes has led to the creation of the 
Registry of Standard Biological Parts and it was indeed the driving force behind notable 
successes such as the production of artemisinin in yeast or the creation of a completely 
chemically synthesized bacterial genome (Cameron, et al. 2014).  
Cognizant of its successes, however, it may be tempting to ignore some of the 
inadequacies of synthetic biology. Efforts to standardize can (and arguably have, in the 
case of synthetic biology) concentrate power, money, and influence to a small geographic 
subset of labs and tastemakers. Not everyone has the ability as J. Craig Venter does to 
have a whole institute devoted to building a fully synthetic bacterial chromosome 
(Gibson, et al. 2010). In that 1.08 million base pair Mycoplasma mycoides genome, JCVI 
inserted various watermarks, including misquoting Feynman‟s “What I cannot create, I 
do not understand” as “I cannot understand what I cannot create” (Gibson, et al. 2010). 
Though trivial and amusing, this error points to an uncomfortable truth: even the best of 
rational design can still miss the mark because of human error. As such, sometimes 
complete control is unnecessary and there is a roll for the uncontrolled: enter directed 
evolution.  
 
Directed Evolution Schemes 
Directed evolution schemes have been around since humans first began 
domesticating animals, farming crops, and brewing beer in 6000 BC (Buchholz and 
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Collins 2013). Though more was accomplished through ignorance of the system than 
knowledge during these early efforts (the details behind fermentation were not worked 
out until the 1850s) their success is undeniable: for instance, a quick look at the size 
difference between modern sweet corn and its ancestor teosinte is ample evidence of 
successful breeding and selection (Buchholz and Collins 2013). As biotechnological tools 
have been developed, the veil of mystery previously cloaking biological phenomenon has 
been lifted. These tools enabled better understanding of the system and, ultimately, the 
building of new systems in experimenter-defined evolutionary contexts and the birth of 
modern directed evolution of biomolecules.    
Modern directed evolution methods share certain commonalities. All usually 
begin with a library of variants (rationally designed, caused by site-directed mutagenesis, 
or allowed to mutate in-vivo) which are then subjected to some sort of selection scheme 
in which each variants genotype is linked to some sort of manifesting phenotype. 
Depending on the method of selection, this manifested phenotype will enable (or disable) 
the further enrichment of that variant, together with other selected-for variants, from the 
previous pool of variants. After this enrichment, the new pool may get further 
mutagenized, experience further rounds of selection, or both. It is important here to 
discern between a screen and a selection within the context of directed evolution. A 
screen “requires the inspection of individual phenotypes” whereas a selection “bypasses 
the need to individually inspect each library member and instead links and activity of 
interest to physical separation of the encoding DNA or survival of the organism 
producing active library members” (Packer and Liu 2015). 
A concrete example of a directed evolution technique mentioned previously is 
phage display technology. A M13 bacteriophage population, each displaying a single-
chain variable fragment (scFv) antibody variant on its surface, can be panned to select for 
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antibodies which bind to a protein of interest (let us use T7 RNA polymerase in this 
example). Bound T7 RNA polymerase on a surface of a well or on beads are washed with 
the phage library. Those scFv variants with partial binding activity to the T7 RNA 
polymerase will bind while those that do not bind will be washed away. Then, the phages 
which contain the nucleic acid code (i.e. genotype) for those high-affinity scFVs are then 
re-amplified via PCR or even through infection and replication in E. coli cells. Phage 
display, together with mRNA, ribosome, and cell surface display, are all subtypes of a 
selection type known as affinity selections (Packer and Liu 2015). Affinity selections are 
powerful technologies which has proven effective as developing therapeutic antibodies as 
well as other binding proteins (Packer and Liu 2015).   
Although affinity selections were some of the earliest directed evolution 
techniques they are far from the only ones. Compartmentalized Self-Replication (CSR) 
used water-in-oil emulsions to isolate individual E. coli cells from each other in which is 
expressed a DNA polymerase variant which would amplify a copy of itself via emulsion 
PCR if that variant was active in the desired selection environment (Ghadessy, et al. 
2001). Compartmentalized Partnered Replication (CPR) extended the CSR technology to 
allow the directed evolution of any gene of interest as long as it could be linked to the 
production of DNA polymerase inside of E. coli cells (Ellefson, et al. 2014). CPR is not 
the only extensible development of a new selection system from a previous methodology: 
a yeast display system, named YESS, has been exploited for the evolution of bond-
cleaving enzymes such as proteases which, when active, cleave and retain an epitope tag 
used to enrich successful variants via FACS sorting (Yi, et al. 2013).  
Yet another example is the exploitation of the production of an antibiotic 
resistance marker or metabolically essential gene (i.e. complemented auxotrophy) 
through some means with the overall survival of a bacterial cell as a whole. A final 
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example of a directed evolution system is phage assisted continuous evolution (PACE) in 
which activity of the gene of interest, which is expressed in an E. coli cell from inside a 
modified M13 bacteriophage genome, is linked to the production of the M13 pIII gene 
which is a coat protein reported to be essential for its replication (Packer and Liu 2015). 
In PACE, the production of the pIII coat protein thus allows active variants to bud out of 
that infected E. coli cell and spread to other, uninfected E. coli cells which are provided 
in a constant in-flow media to replace spent and infected media (Packer and Liu 2015). 
These last two selections, antibiotic selection/complemented auxotrophy and 
PACE, are distinct from those previous mentioned because they are usually ran as 
continuous selections. Continuous selections (unlike affinity selections, CSR, CPR, and 
YESS systems, which are discrete selections) are set up in such a way to allow for all of 
the aforementioned steps of selection (creation of variation, pressure of selection to select 
for favorable variants, and enrichment of those variants) to occur at the same time. In 
theory, continuous evolution is advantageous because it minimizes the amount of time 
and manual work necessary to turn rounds relative to discrete selection methodologies. In 
practice, continuous evolution strategies can be particularly finicky to set up and, by their 
continuous nature, suffer the disadvantage of allowing so-called “cheaters”, variants 
which have somehow short-circuited the selection, to quickly come to dominate the 
variant library population.    
What is the roll of directed evolution in the era of synthetic biology? Efforts 
towards biological standardization via synthetic biology are imbued with an implicit 
hubris: it may be that certain aspects of biological phenomena are too complex to lend 
themselves to systemization. Engineering biology, unlike other engineering disciplines, is 
not obviously governed by a simple series of equations but, rather, united by one 
universal theme: evolution happens. Evolution is the great unifier among all biological 
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phenomena. Because of this, much work has been done in order to study not just how 
evolution works and but also into controlling, accelerating, and biasing it in a laboratory 
setting. The former work can be generally classified as “evolutionary biology” and the 
latter called “directed evolution”. In this dissertation, work will be presented which blurs 
the lines between evolutionary biology and directed evolution yielding unanticipated 
outcomes and new methods of biological control. This work provides evidence that 
although the ability to rationally design biology is important, various ways to rationally 
control and direct evolution offer a complementary strategy to the systematization of 
synthetic biology. 
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CHAPTERS 
 
Chapter 1: Predicting Evolution of the Transcriptional Regulatory Network in a 
Bacteriophage 
 
Abstract  
Prediction of evolutionary paths has been a desirable but elusive goal, and 
requires a deep knowledge of both underlying mechanisms that relate genotype to 
phenotype, and an understanding of how phenotype impacts organismal fitness. We have 
relied on foreknowledge of the sequence specificity of a T7 RNA polymerase variant 
(G78-KIRV) that recognizes a unique promoter that is three nucleotides away from the 
wild-type to predict and guide the evolution of the entire bacteriophage T7 regulatory 
network. A mutant of T7 phage lacking its RNA polymerase gene was passaged on a 
bacterial strain providing G78-KIRV in trans, resulting in higher overall fitness in the 
population. As the phage adapted to G78-KIRV, we anticipated the evolutionary paths to 
higher fitness could be predicted based on in-vitro transcription rates of various 
promoters. The predictions failed to capture some of the promoter evolution pathways, 
but these in turn revealed new insights into the promoter specificities of the G78-KIRV 
polymerase, further demonstrating the close predictive relationship between sequence 
specificity and phage fitness. Overall, this study points toward the feasibility of 
predicting evolution in well characterized, simple systems.   
 
Introduction 
The historical dichotomy between studying living systems through reductionist 
molecular biology or holistic evolutionary biology has given way to a unification termed 
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the functional synthesis (Dean and Thornton 2007). This synergistic approach is 
increasingly used to empirically validate evolutionary hypotheses and has been applied to 
such disparate subjects as insecticide resistance, mouse coat color, and antibiotic 
resistance (Dean and Thornton 2007; Hoekstra, et al. 2006; Newcomb, et al. 1997; 
Weinreich, et al. 2006). A long-term goal of the functional synthesis that may now be 
within reach is evolutionary prediction of both phenotypes and the genetic pathways 
leading to those phenotypes. Predicting organismal moves on a fitness landscape requires 
systems in which the genotype-phenotype relationship is well-characterized, and the 
fitness consequences of the different phenotypes are also understood. At this time, these 
properties are most feasibly extracted from systems in which there are relatively few 
alternative molecular states that nonetheless have major effects on fitness. 
Among the simplest, yet still complex, systems that are particularly amenable to 
evolutionary prediction is the transcriptional regulatory network of bacteriophage T7. 
Bacteriophage T7 is a lytic, 40kB dsDNA podovirus that infects E. coli (Molineux 2006). 
The genome encodes nearly 60 genes and is unusual among phages in that most gene 
expression requires a phage-encoded RNA polymerase. Gene expression is controlled by 
17 phage promoters in the genome, and there are a number of overlapping transcripts. 
However, underlying this complex regulatory network is a single phage RNA polymerase 
(T7 RNAP) that interacts with a highly defined and well-characterized promoter. We and 
others have previously used protein engineering and directed evolution to craft T7 RNAP 
variants that recognize alternative promoter sequences (Ellefson, et al. 2014; Meyer, et al. 
2015).  
In particular, we have generated a T7 RNAP variant, G78-KIRV (Ellefson, et al. 
2014) that can utilize a promoter variant that is three nucleotides away (CGG) from the 
wild-type T7 promoter (GAC) at positions -11 to -9 (Rong, et al. 1998), and that is 
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orthogonal to the wild-type, in that the polymerases cannot readily cross-utilize one 
another‟s promoters. The synthetically-derived G78-KIRVpolymerase enables us to 
perturb the regulatory network of T7 phage, and to observe the adaptation of the network 
to a major shift in specificity of the transcriptional apparatus. Most importantly, the 
observed evolutionary pathways for promoters can be compared with initial predictions 
based on the known and fixed promoter specificities of the mutant G78-KIRV.  
 
Results 
Initial prediction of a single mutation path to a mutant promoter triplet 
The G78-KIRV RNA polymerase was a product of directed evolution; 
presumably it had never before been experienced in the evolutionary history of the wild-
type T7 phage. Thus, it was unclear to what extent the native bacteriophage T7 was able 
to evolve in response to this polymerase. This was especially true given that the 
polymerase had been evolved to transcribe from a promoter that was three mutations 
from the consensus T7 promoter. By forcing T7 the use this new RNA polymerase in 
place if its own, the phage was confronted with a potentially deep fitness valley that 
required the acquisition of several mutations to regain robust replication during 
passaging.   
To determine the most likely single-step evolutionary paths for the bacteriophage 
promoter network utilizing G78-KIRV RNAP, we carried out in-vitro transcription 
assays using purified G78-KIRV RNAP on the wild-type T7 promoter (GAC), on the 
CGG G78-KIRV promoter, as well as on the three single- and three double-mutant 
promoters intermediate between the wild-type and the G78-KIRV promoter (Figure 1.1). 
These transcription reactions confirmed the previously observed orthogonality (lack of 
activity of heterologous promoter-RNAP combinations) but, more importantly revealed 
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the transcriptional activity of the six intermediate mutant promoters (Figure 1.1).  While 
G78-KIRV RNAP had been evolved to transcribe only the mutant promoter triplet CGG, 
it nonetheless (and not surprisingly) had a higher activity on the six intermediate mutant 
promoters than on the T7 wild-type triplet (GAC). Of the three promoters one mutation 
from wild-type, the GAG promoter displayed the highest activity. Of the three double 
mutants, both the CAG and GGG promoters displayed higher transcriptional activity than 
CGC (Figure 1.1). These results thus provided a foundation for predicting the evolution 
of T7 RNAP promoters in the phage challenged with G78-KIRV polymerase. 
T7 evolves to use the alternative polymerase 
In initiating the evolution of wild-type T7 in response to the new RNA 
polymerase (G78-KIRV), we first determined whether a phage variant whose genome 
lacked the wild-type RNAP gene (T7Δ1) could grow with the G78-KIRV polymerase 
expressed in trans from a plasmid. T7Δ1 was complemented by the plasmid, but its 
plaques were noticeably smaller than plaques of wild-type T7 (Figure 1.2), suggesting a 
fitness deficiency. The fact that plaques could be generated at all was surprising given the 
3 mutation distance between the optimal triplet for G78-KIRV and the promoters found 
in T7 wild-type.  It seems likely that the overexpression of the G78-KIRV polymerase 
before phage infection is at least partially responsible for the complementation observed. 
The reduced initial growth meant that the phage could be expected to evolve higher 
fitness after serial passaging, as seen in the previous study complementing T7Δ1 with 
bacteriophage T3 RNAP (Bull, et al. 2007). 
Four replicate lines of T7Δ1 were subjected to repeated serial transfer on the 
complementing host (Fig. 1.3).  By providing the RNAP in trans, all regulatory evolution 
was forced to occur in the promoters.  BL21 E. coli cells harboring the G78-KIRV RNAP 
expression plasmid were grown for one hour with 100uM IPTG induction, at which point 
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T7Δ1 phage were added at a multiplicity of infection (MOI) of 0.01-0.1 and the culture 
grown until lysis. This protocol allowed expression of the complementing RNAP in all 
cells prior to phage infection. The parental T7Δ1 lysed the culture within ~90 minutes, 
whereas either wild-type T7 phage or T7Δ1 with the wild-type polymerase provided in 
trans fully lysed the culture in ~30 minutes. Over the course of the first 50 passages the 
lysis time decreased, ultimately going from 90 minutes to 30 minutes in the presence of 
IPTG induction (Figure 1.4). At this point, serial passaging was continued without IPTG 
induction, relying only on the leakiness of the LacUV5 promoter to drive expression of 
the G78-KIRV RNAP. This resulted in an initial increase in culture lysis time to ~60 
minutes, which then again decreased back to ~30 minutes during passages 51-100 (Figure 
1.5).  
After 100 passages the culture lysis time dramatically decreased in all four 
replicates – measured on un-induced G78-KIRV RNAP cells (Figure 1.6A). Because 
time to lyse a culture is an indirect fitness measure, fitness assays of growth on plates 
were performed in which phage were allowed to grow for a fixed time on un-induced 
G78-KIRV RNAP cells. Fitness assays were carried out for the wild-type T7 phage, the 
ancestor T7Δ1 phage, and the four evolved T7Δ1 phage lines at passage 100. These 
fitness assays showed that the four evolved strains reached nearly the same doublings per 
hour as wild-type T7 phage on un-induced G78-KIRV RNAP cells (Figure 1.6B) and we 
therefore set out to determine the mutations for increased fitness–presumably to the 
regulatory network of the T7 promoters. 
Limited promoter changes and promoters that changed in the evolved lines  
All four adapted lines were sequenced at two time points, after transfer 50 and 
after transfer 100 (utilizing MiSeq 2x250 reads with at least 3.6x105 reads per sample). 
Across the four lines, substitutions occurred in only five of the 16 T7 promoters: ϕOL, 
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ϕ1.5, ϕ2.5, ϕ6.5, and ϕOR (Figure 1.7). In the initial 50 passages all four lines exhibited 
an anticipated GAG single change toward the promoter specificity of G78-KIRV in one 
to three of the promoters (Table 1.1). But unanticipated CCC and GCC changes were also 
observed in all four lines in one to three of the promoters (Table 1.1). By passage 100, 
promoters were found with two substitutions toward the G78-KIRV triplet (Figure 1.7).  
But yet another unanticipated change (AAG) was found in one to two promoters in two 
lines (Table 1.1, Figure 1.8).  
Individual promoters followed different paths. Most promoters failed to evolve at 
all, but even those that did evolve often failed to carry the same substitutions as others 
that evolved. The ϕ2.5 promoter evolved in only one of the four lines (in line 3 to GAG), 
and the mutation did not fix in the population, occurring in 46.6% of the phage by 
passage 50 but only 25.6% by passage 100 (Figure 1.8, Table 1.2). In contrast, the ϕ1.5 
promoter evolved to GAG all four populations by passage 50 and remained fixed through 
passage 100. These two promoters can be viewed as the limit cases for others; in one case 
(the ϕ2.5 promoter evolution in a fraction of line 3) virtually no evolution occurred, and 
in the other (the rapid fixation in all lines at the ϕ1.5 promoter), there was rapid evolution 
toward a single endpoint, suggesting strong selection for a particular sequence.  
The ϕOR promoter first evolved to GCC in all four lines by passage 50, but then 
proceeded to evolve into a heterogeneous mixture of GCC, GGG, AAG, GAG, and CCC 
by passage 100 (Figure 1.7).  
Interestingly, the non-canonical ϕOL promoter, which contains AAC at positions 
that correspond to the consensus GAC, followed a different path, evolving to AGC in 
39% of the line 4 population by passage 50 (Table 1.2) (Dunn and Studier 1983). By 
passage 100, the ϕOL promoter in lines 1, 2, and 3 evolved to ACC and additionally to 
AGC in line 3 (Figure 1.7, Table 1.2). Unexpectedly, the AGC substitution in 39% of the 
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line 4 population at passage 50 decreased to only 3.2% of the population by passage 100 
(Table 1.2). This coincided with and may possibly be explained by widespread 
duplication of the ϕOL promoter in all lines by passage 100, including duplications with 
mutant promoters (Figure 1.7, Table 1.2).       
The ϕ6.5 promoter seemed to follow a combination of these paths.  It was 
extremely heterogeneous at both passage 50 (GAC, GAG, CCC, and GCC) and 100 
(GAG, CCC, GCC, GGG, and AAG), and also eventually duplicated in lines 2, 3, and 4 
(Figure 1.7, Table 1.2). 
Evolution outside of promoters 
Following 50 passages, the four lines each had fixed between 2-7 non-promoter 
substitutions (Table 1.3). Following 100 passages, the four lines had between 1-6 fixed 
non-promoter substitutions (Table 1.3). Interestingly, the lines after 100 passages retained 
only a fraction of the fixed substitutions observed at 50 passages (with one line losing all 
of the fixed, non-promoter mutations, two lines retaining one mutation, and one line 
retaining two mutations). The fact that most molecular evolution occurred within 
promoters is consistent with the expectation that most selection operated on polymerase-
promoter binding. Of note, the only fixed non-promoter mutation found in all of the lines 
was an E34K mutation in the major capsid protein. 
In-vitro transcription of unanticipated promoter triplets 
The promoter triplets GCC, CCC, and AAG had not been tested for in-vitro 
activity because they were not on the direct evolutionary pathway between wild-type and 
G78-KIRV promoter sequences. After discovering these triplets in the evolved phages, 
purified wild-type and G78-KIRV RNAPs were tested for their activities on these new 
promoters (Figure 1.8 and 1.9). In line with the serial passaging results, G78-KIRV 
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RNAP was as active as or more active on these three unanticipated promoters than on the 
three predicted single-step mutants (Figure 1.9). 
 
Discussion 
This is the first example in which the evolutionary landscape of a system 
component has been used to perturb and predict the evolution of an interacting system as 
a whole, in this case the bacteriophage T7 RNA polymerase and the bacteriophage T7, 
respectively.  The fact that the laboratory-evolved G78-KIRV T7 RNA polymerase 
variant has no apparent counterparts in nature, and that the promoter utilized by this 
polymerase requires at least three mutations from the wild-type T7 consensus promoter 
for optimal transcription activity, means that challenge experiments favor an evolution 
that should be novel to the phage in several respects. The experiment thereby tests basal 
issues in how adaptation can occur in complex systems.  
At the outset we formed a prediction matrix (Figure 1.1) for the most likely 
evolutionary path in response to the novel transcription machinery. The T7Δ1 phage used 
in our selections has 16 promoters that could potentially evolve, yet mutations evolved in 
only 4 - 5 of these.  Interestingly, these were the same promoters that evolved in a 
previous study in which T7Δ1 was forced to use T3 RNAP.  Use of T3 RNAP requires 
only a single mutational change in a promoter to achieve high transcription activity (Bull, 
et al. 2007). The similarity between the two studies suggests that these promoters are the 
primary transcriptional hubs that are under the highest selective pressure.   
 It is unexpected that so few of the 16 T7 promoters evolved to accommodate the 
new RNAP, but also not implausible.  The relative spacing of the mutant promoters 
suggests that the inherent processivity of the T7 RNAP is high enough to result in 
sufficient gene expression of essential phage genes along the T7 genome.  The T7 
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genome has two known terminators, one for E. coli RNAP at position 7555 and one for 
T7 RNAP immediately after gene 10 at position 24,170.  Transcription from the 3 E. coli 
promoters in the initial 750bp of the phage genome by the E. coli RNAP produces 
transcripts of up to 7kB (Molineux 2006). The ϕ1.5 and ϕ2.5 phage promoters, which 
start at nucleotides 7761 and 9090, respectively, are approximately 10kB away from the 
ϕ6.5 promoter, and in the absence of downstream promoters, the ϕ6.5 promoter would 
need to transcribe approximately 20kB to produce all of the necessary late genes. While 
transcripts from these promoters alone would be quite long, T7 RNA polymerase has the 
ability to transcribe up to 27kB in-vitro and up to 32kB in-vivo (Mairhofer, et al. 2013; 
Schelle 2002). Alternatively, G78-KIRV RNAP may still have enough activity on the 
remaining wild-type promoters to enable limited transcription. 
The evolutionary paths chosen made sense in terms of the transcription activities 
of the G78-KIRV RNAP (Figure 1.8). Three of the six promoters that evolved followed 
the single and double mutant paths expected. For the three that did not, the mutations that 
accumulated revealed new, highly active promoter variants (Figure 1.8, 1.9). Overall, the 
data from in-vitro transcription experiments was surprisingly predictive of the 
evolutionary paths taken by the phage in-vivo. Single mutant paths at passage 50 had, by 
passage 100, continued to accumulate functional mutations (e.g. ϕ6.5 in line 3; Figure 
1.7).  Some paths seen in one line at passage 50 were reproduced in other lines by 
passage 100 (e.g. ϕOR in lines 2, 3, and 4; Figure 1.7). It should be noted, however, that 
no promoter in any of the 4 replicate lines evolved the triplet on which the G78-KIRV 
RNAP was evolved. We acknowledge that our selection here when the RNAP is already 
present in the cell may lead to different outcomes than a selection when the RNAP needs 
to be expressed from the incoming genome.   
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Beyond changes in promoter identities, promoters in all four lines experienced 
duplication events (Figure 1.7). Most occurred after transfer 50, under conditions of low 
expression of the mutant RNAP (Table 1.2), and thus represented a different solution 
than point mutations to the problem of how to regain adequate transcription activity. All 
four lines duplicated and mutated their ϕOL promoter, presumably supporting the 
function of the ϕOL promoter to direct T7 RNAP-mediated genome entry into the host 
cell (Garcia and Molineux 1995). Similarly, the E. coli A2 promoter near the ϕOL 
promoter at the 5‟ end of the phage genome duplicated in experimental line 4 (Table 1.2).   
Empirical recapitulations of mutational pathways such as those demonstrated in 
this work can yield insights to how enzymes and organisms traverse fitness landscapes 
(Poelwijk, et al. 2007). As but one example, the TEM-1 β-lactamase enzyme that is 
known to have high activity towards ampicillin can also evolve the ability to degrade a 
structurally different lactam, cefotaxime, via five mutations (Weinreich, et al. 2006). 
Assaying fitness for all possible combinations of these five mutations revealed that 18 of 
the 120 possible mutational pathways resulted in stepwise, monotonic fitness increases 
toward cephalosporinase activity, with 10 pathways being most feasible. This mirrors our 
own results, in which only a fraction of feasible single-step paths were taken (Figure 
1.10). Similarly, other work on the recapitulation of mutational steps in higher-order 
regulatory networks, such as hormone receptor:binding sites and repressor:operator 
interactions, have reinforced the notion that multiple different single-step evolutionary 
paths lead to diverse movements on fitness landscapes (Bridgham, et al. 2006; Lehming, 
et al. 1990).  
One difference between these systems, though, is that unlike the hormone 
receptor:binding sites and repressor:operator interactions, phage promoters displayed no 
evidence of so-called sign epistasis in which an initial sampling of a lower-activity 
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variant was required before subsequent evolution to a higher activity position. This is 
perhaps because the adaptation of a promoter to a polymerase is something that occurs 
frequently during evolution; indeed, one can view the promoters in any genomic system 
as being „rheostats‟ that adapt by point mutation to balance the expression of multiple 
different genes. The sequence changes we observed during phage evolution further 
emphasize this point, in that they followed „productive‟ single mutational paths that 
likely altered expression levels. Beyond single mutations, the sequence space of 
promoters within two mutations of the wild-type promoter in the -11 to -9 region is 
occupied by N=36 possible states (9 single mutants and 27 double mutants) and is 
populated by all six of the promoter variants from the evolution experiment (Figure 1.10). 
This suggests that there are several productive paths that in turn further diversify into 
multiple, viable solutions on a complex fitness landscape. That said, it is unknown at 
present what portions of the sequence and fitness landscapes may have been restricted to 
the phage because it was moving only by single mutations. 
Assuming that the evolution results speak to natural selection, extensive promoter 
heterogeneity and duplication in wild phage should be observed. Indeed, single-subunit 
T7-like RNAPs with wildly different promoter sequences have been identified not just in 
other bacteriophages but also in eukaryotic mitochondria and plant chloroplasts (Bohne, 
et al. 2016; Cermakian, et al. 1997), consistent with regulatory fitness landscapes that are 
only moderately rugged, and that conjoin multiple optima within easy reach of one 
another. 
 
Conclusion 
These enzyme evolution and regulatory interaction studies are useful in displaying 
critical features of evolutionary pathways, and they thus lead us to the prospect of 
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predicting the evolution of systems. This prediction of evolutionary paths is what we 
present here. Our choice to use a heterologous T7 RNAP to evolve T7Δ1 phage was due 
to the fact that the system is well-characterized down to the promoter bases involved in 
polymerase recognition, that different RNAPs were available, and that the phage is easily 
evolved (Bull, et al. 2007; Ellefson, et al. 2014; Rong, et al. 1998). Overall, it has been 
possible to predict much of the evolutionary trajectory of a bacteriophage in response to a 
synthetically-created component, and our work points toward the next step in the 
functional synthesis by a priori predicting rather than post hoc confirming evolutionary 
trajectories. Even more importantly, the fact that multiple pathways led to a recovery or 
near-recovery of fitness on a very short evolutionary time-scale may point the way to 
understanding why different types of biological systems move to position themselves in 
different local geographies of a fitness landscape. 
 
Materials and Methods 
Phage Passaging 
Frozen aliquots of BL21-Gold cells (Agilent) transformed with pLUV-G78-
KIRV-RNA polymerase (wild-type T7 RNA polymerase with Q744K, L747V, N748H, 
L749I, R756E, L757M, H772R and E775V mutations, from Ellefson et al., 2014) were 
thawed and used to inoculate 10mL of 2xYT with proper antibiotic and grown at 37° C to 
achieve a density of 10
8
 cells/mL at 60 minutes. For the first 50 passages, isopropyl-L-
thio-β-galactoside (IPTG) was added to a concentration of 1mM before the 60 minutes of 
growth (no IPTG addition for the second 50 passages). After 60 minutes to reach density, 
1uL of previous bacteriophage lysate was added (a 10
-4 
dilution, transferring 
approximately 10
7
-10
8
 phage). Bacteriophage was allowed to grow under the same 
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conditions, occasionally allowing the cultures to reach full lysis in order to stimulate 
recombination.  
RNA polymerase purification  
RNA polymerases were purified via Ni-NTA N-terminal 6xHis methods in a 
manner similar to elsewhere (Ellefson, et al. 2014). Briefly, pQE-WT/G78 RNA 
polymerase variants each respective RNA polymerase under the control of a T5 
promoter/Lac operator, were transformed into BL21-Gold cells and grown overnight in 
4mLs 2xYT.  The next day, cells were diluted into 50mLs of 2xYT media and grown to a 
density of OD600 ~0.6-0.7, when they were induced with 1mM , isopropyl-L-thio-β-
galactoside (IPTG). These cells were allowed to grow for 14-16 hours at 18° C, at which 
point they were pelleted by spinning in centrifuge at 4000g and re-suspended in 30mLs of 
binding buffer (500mM NaCl, 5mM imidazole 50mM Tris pH 8). This was sonicated at 
50% amplitude for 2 minutes (1s ON, 1s OFF) in an ice bath. Lysed cells were spun at 
10,000g for 30 minutes, then the supernatant was added to a 1mL Ni-NTA resin column 
which had been equilibrated with 2x binding buffer. The cells were washed with 6x 
column volumes of wash buffer (500mM NaCl, 20mM imidazole, 50mM Tris pH 8) then 
eluted into 3mLs of elution buffer (500mM NaCl, 250mM imidazole, Tris pH 8). These 
samples were dialyzed into 1.2L of dialysis buffer (300mM NaCl, 1mM EDTA, 1mM 
DTT, 50mM Tris pH 8) overnight and again into 1.2L of storage buffer (100mM NaCl, 
1mM EDTA, 1mM DTT, 50mM Tris pH 8) overnight. The resulting protein was adjusted 
to 1mg/mL and added to equal volumes of glycerol.    
In-vitro transcription 
In-vitro transcription was done in a manner similar to elsewhere (Ellefson, et al. 
2014). In-vitro transcription reactions of the spinach aptamer consisted of 40mM Tris-
HCl pH 7.0, 30mM MgCl2, 6mM spermadine, 6mM each NTP, 10mM DTT, 0.5uM T7 
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RNA polymerase, 0.5uM DNA template and 0.17mg/mL DFHBI in DMSO. Reactions 
were incubated at 37° C, and were read every minute at an excitation/emission of 
469nm/501nm for 2 hours in a Safire monochromator (Tecan). DNA templates were 
made by thermal cycling 2uM forward primer and reverse primers (see Table 1.4) with 
Accuprime Pfx in its buffer using the following, then gel purified:  (94 °C:2 min, 12 
cycles (94 °C:15 s, 50 °C:30 s, 68 °C:30 s), 68 °C:1 min).     
Lysis curves 
Cells were grown in a manner identical to those of the passaging scheme (achieve 
a density of 10
8
 cells/mL) and 150uL of cells were added to each well of a clear, 96-well 
plate. The proper concentration of isopropyl-L-thio-β-galactoside (IPTG) (where 
required) was added to each well, as, too, was the proper concentration of bacteriophage 
(determined by previous titer) in order to give the required MOI (MOI for lysis curves 
here=0.01). The plate were grown in a PowerWave 340 microplate spectrophotometer 
(BioTek) at 37° C and OD600 readings were taken every minute, preceded by shaking for 
10 seconds and intensity level 4.  
Preparing frozen cell stocks for fitness assay 
pLUV-G78-KIRV-RNA polymerase plasmid variants was electroporated into 
BL21-Gold cells and plated overnight. The next day, the lawn was scraped off and put 
into 10mL of 2xYT with proper antibiotic and grown for 2 hours, after which point 5mLs 
was put into 300mLs of 2xYT and grown for an additional hour. The cells were then 
centrifuged for 20 minutes at 4000g. The 2xYT was decanted and the cell pellets were 
resuspended in 5mLs of 20% 2xYT glycerol before freezing in -80° C. Cell samples were 
withdrawn and concentrations were found which gave and OD600 ~1.00 after 1 hour of 
growth when added to 10mL of 2xYT with proper antibiotic (correlating to 108 
cells/mL). All fitness assays were done using the same frozen stocks. 
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Fitness assays 
 Less than 50 fresh plaque forming units (passaged and titered within last four 
days) were added to 4mLs of top agar, 350uL of bacteria grown for 1 hour to an OD600 
~1.00 (a density of 10
8
 cells/mL), and 50mg/mL kanamycin before plating on Kanamycin 
plates. Plates were incubated for 3 hours, top agar was removed with spatula and added to 
15mL falcon tubes, to which 4mLs of 2xYT and 1 mL chloroform was added and 
vortexed, then allowed to sit at 4° C for at least 1 hour. The tubes were then spun at 
4000g for 15 minutes at 4° C. The aqueous layer after spinning was 5mL. The phage titer 
of the aqueous phase was then measured. 
Sequencing and Sequence Analysis 
Miseq 2x250 paired end reads were taken using purified bacteriophage DNA and 
aligned to the T7 bacteriophage genome (GenBank V01146.1) using breseq (Deatherage 
and Barrick 2014). At least 3.6x10
5
 reads were taken for each sample. The breseq output 
was then analyzed by to identify promoter changes. 
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Figures 
 
Figure 1.1: Promoters and Single-step prediction matrix from wild-type to G78-KIRV 
promoter 
 
 
 
Figure 1.1: A. Wild-type (red) and G78-KIRV (blue) T7 RNA polymerase promoters. B. 
In-vitro activity of G78-KIRV RNA polymerase on wild-type (GAC), G78-KIRV (CGG), 
and intermediate promoters. G78-KIRV RNA polymerase was purified and used for in-
vitro transcription using a linear dsDNA spinach template with each of the respective 
promoters (See Table 1.4). Fluorescence after 1 hour was taken in triplicate shown with 
standard error as a percentage of G78-KIRV T7 RNA polymerase activity on its cognate 
promoter (CGG). C. Single-step prediction matrix shows the six intermediate promoters 
as they take single-steps from the wild-type promoter to the G78-KIRV promoter. The 
boxes are shaded relative to each respective promoter activity using G78-KIRV RNA 
polymerase and arrows show the hypothesized most likely steps through mutational space 
based on based on in-vitro transcription activity assay. Percentage activity of G78-KIRV 
RNA polymerase on the CGG promoter is shown in parentheses.   
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Figure 1.2: Phage plaques on BL21-Gold E. coli cells induced with 1mM pLUV-G78-
KIRV RNA polymerase 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Phage plaques on BL21-Gold E. coli cells induced with 1mM pLUV-G78-
KIRV RNA polymerase. Wild-type T7 bacteriophage population (left) and the ancestor 
T7Δ1 (right).  
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Figure 1.3: Passaging scheme 
 
 
 
 
 
Figure 1.3: Passaging scheme over course of experiment. Four replicate T7Δ1 phage lines 
were initially subjected to 50 passages on BL21 cells expressing the G78-KIRV RNA 
polymerase mutant using 100uM IPTG in trans (i.e. from a plasmid). Passaging was 
continued for another 50 passages in the same manner using 0uM IPTG induction.  
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Figure 1.4: Plate reader-based lysis assays of the four passage 50 isolates 
 
 
 
 
 
Figure 1.4: Plate reader-based lysis assays of the four passage 50 isolates. Passage 50 
isolates were tittered and used to infect either 100uM IPTG induced pLUV-G78-KIRV 
RNA (A) or 100uM IPTG induced pLUV-WT-RNAP (B) cells at an MOI=0.01. Error 
bars represent standard deviation.  
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Figure 1.5: Minutes per passage 
 
 
 
Figure 1.5: Minutes per passage. The four replicate phage populations lysed consistently 
within two minutes of each other. Phage lysis time, defined here as the amount of time to 
clear the 10mL flasks of mid-log E. coli cells after addition of 1uL of previous lysate, 
decreased during both the first fifty passages with high expression of the G78-KIRV 
RNA polymerase (blue) as well as the subsequent fifty passages with low expression of 
the RNA polymerase (51-100, red). 
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Figure 1.6: Lysis time and fitness assays after 100 passages 
 
 
 
Figure 1.6: A. Whole culture lysis curves (MOI=0.01) for each of the four evolved strains 
after 100 passages (approximately 72 hours of adaptation) relative to the original T7Δ1 
ancestor. B. Plate growth fitness assays (calculated as doublings/hour) comparing WT 
T7, T7Δ1, and the four evolved strains after 100 passages. The WT T7 phage carries its 
own RNAP, so the complementation provided by these hosts is not necessary.  Note that 
these assays were conducted from the increase in titer during three hour growth on plates; 
the growth rate under these conditions is far less than in liquid (Bull, et al. 2011). 
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Figure 1.7: Promoters mutated from the wild-type T7 promoter in the course of the 
experiment 
 
 
 
 
 
Figure 1.7: Above, map of the T7Δ1 genome with the 16 T7 promoters as green triangles 
and the T7 terminator as orange octagon. The five promoters mutated during the course 
of the passaging are shown in red boxes. Below, the five promoters in each of the four 
lines showing the mutant promoters (red boxes) from the canonical promoters (black 
boxes) at passage 100. Duplications are identified with an asterisk (*) 
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Table 1.1: Promoter identities as they occurred during the passaging. 
 
 
 
Table 1.1: Promoter identities as they occurred during the passaging.  
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Figure 1.8: Predicted vs. actual promoter changes in the passaging 
 
 
 
Figure 1.8: Predicted (on left, as before) and actual mutations (on right) found during the 
passaging. Actual paths (red promoters) on right are shown with arrows and pathway 
boxes are shaded according to activity. Activity as a percentage of G78-KIRV T7 RNAP 
on CGG promoter is displayed in parentheses below each triplet (Figure 1.1 and Figure 
1.9). Those promoters found that matched the prediction are underlined whereas those 
unanticipated by the prediction are boxed.  
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Table 1.2: Promoter mutations and duplications as they occurred during the passaging. 
 
 
Table 1.2: Promoter mutations and duplications as they occurred during the passaging. 
No promoter changes are shown in white boxes, partial percentages are shown in grey 
boxes, and 100% fixed promoter changes are shown in black boxes.   
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Table 1.3: Breseq output of all the non-promoter fixed mutations in each of the four 
populations at passage 50 and 100. 
 
 
 
Table 1.3: Breseq output of all the non-promoter fixed mutations in each of the four 
populations at passage 50 and 100. All four lines picked up the E34K mutation in their 
major capsid protein by passage 100.  
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Figure 1.9: In-vitro transcription activity of wild-type and G78-KIRV RNA polymerases 
 
 
 
Figure 1.9: In-vitro transcription activity of wild-type and G78-KIRV RNA polymerases 
on wild-type (GAC, in red) and heterologous G78-KIRV promoter (CGG, in blue) as 
well as additional promoters found in the phage evolution (CCC, AAG, and GCC, in 
purple). All values normalized to G78-KIRV RNA polymerase activity on G78-KIRV 
(CGG) promoter defined as 100. 
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Figure 1.10: Visualization of various sequence spaces. 
 
 
 
 
Figure 1.10: Visualization of various sequence spaces. (Left) The single-step map 
showing the six intermediates between the wild-type and G78-KIRV promoter. (Middle) 
a representation of all of the 36 promoters within two mutations of the wild-type 
promoter (those found in the experiment boxed in red). (Right) Representation of the 
totality of possible sequences in -11 to -9 region of the T7 promoter (N=64). Each axis 
includes four positions, one for each of the four nucleotides. Colors are used to articulate 
theoretical differential promoter activity.  
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Table 1.4: Primers used for in-vitro transcription 
 
 
 
Table 1.4: Primers used for in-vitro transcription (See Materials and Methods). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DJG.GACT.SpMX1.F AATATAATACGACTCACTATAGAGGAGACTGAAATGGTGAAGGACGGGTCCAGTGCTTCG 
DJG.CACT.SpMX1.F AATATAATACCACTCACTATAGAGGAGACTGAAATGGTGAAGGACGGGTCCAGTGCTTCG 
DJG.GGGT.SpMX1.F AATATAATACGGGTCACTATAGAGGAGACTGAAATGGTGAAGGACGGGTCCAGTGCTTCG 
DJG.CAGT.SpMX1.F AATATAATACCAGTCACTATAGAGGAGACTGAAATGGTGAAGGACGGGTCCAGTGCTTCG 
DJG.CGCT.SpMX1.F AATATAATACCGCTCACTATAGAGGAGACTGAAATGGTGAAGGACGGGTCCAGTGCTTCG 
DJG.GAGT.SpMX1.F AATATAATACGAGTCACTATAGAGGAGACTGAAATGGTGAAGGACGGGTCCAGTGCTTCG 
DJG.GGCT.SpMX1.F AATATAATACGGCTCACTATAGAGGAGACTGAAATGGTGAAGGACGGGTCCAGTGCTTCG 
DJG.CGGT.SpMX1.F AATATAATACCGGTCACTATAGAGGAGACTGAAATGGTGAAGGACGGGTCCAGTGCTTCG 
DJG.CCCT.SpMX1.F AATATAATACCCCTCACTATAGAGGAGACTGAAATGGTGAAGGACGGGTCCAGTGCTTCG 
DJG.AAGT.SpMX1.F AATATAATACAAGTCACTATAGAGGAGACTGAAATGGTGAAGGACGGGTCCAGTGCTTCG 
DJG.GCCT.SpMX1.F AATATAATACGCCTCACTATAGAGGAGACTGAAATGGTGAAGGACGGGTCCAGTGCTTCG 
DJG.SpMX1.R GAAAAGACTAGTTACGGAGCTCACACTCTACTCAACAGTGCCGAAGCACTGGACCCG 
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Chapter 2: Evolution of the Transcriptional Apparatus in an Evolutionarily 
Polarized Bacteriophage Population 
 
Abstract 
With the emergence of synthetic biology, it remains unclear how far synthetic 
parts (with altered activity and substrate specificity) can alter the evolutionary trajectory 
of a host organism. Previously, we had evolved bacteriophage T7 populations (T7Δ1) on 
a synthetically-evolved T7 RNA polymerase (G78-KIRV) leading to recovery of fitness. 
Here, we further interrogated these evolutionarily polarized populations by recombining 
either the wild-type or the synthetic RNA polymerase into the bacteriophage genomes 
and allowing further adaption to take place in order to discover more about the 
evolvability of the transcriptional apparatus writ large. The evolved strains were able to 
accommodate insertion of the synthetic polymerase back into their genomes, whereas the 
ancestor T7Δ1 was not. Furthermore, the bacteriophage populations subsequently altered 
the transcriptional apparatus such that the synthetic polymerase was further mutated 
(rather than promoters) to create two distinct types of RNA polymerase generalists. This 
work is an example of how evolutionary optimization is both essential for simple design 
implementation in even the most characterized of biological systems and powerful in 
enabling evolution to discover unexpected solutions. Additionally, our work raises the 
question whether synthetic biology and directed evolution can be used for laboratory 
speciation events and the development of orthogonal viruses. 
 
Introduction 
Laboratory-based evolution has long been a tool to study how evolution works in 
well-defined systems. Laboratory-based evolution studies have been applied to a wide-
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variety of applications such as studying the utilization of a new carbon source, replaying 
the evolutionary “tape-of-life” in order to interrogate evolutionary stochasticity, and even 
inviting the adoption of unnatural amino acids into essential proteins (Blount, et al. 2012; 
Dickinson, et al. 2013; Hammerling, et al. 2014). These studies allow empirically-derived 
conclusions to drive understanding of fundamental aspects of evolution. In parallel, what 
is now known as synthetic biology has inherited the goal passed on by genetic 
engineering of being able to design, engineer, and control biological processes. Unlike 
genetic engineering, however, synthetic biology hopes to achieve this goal of design, 
engineering, and control of biological processes via standardization of design processes, 
assays, and genetic parts (Galdzicki, et al. 2014; Gardner and Hawkins 2013). This 
process of standardization has led to a demand for well-characterized genetic parts in 
which more complicated genetic circuits can be faithfully and reliably built in a variety of 
organisms. These parts, acquired by both part mining the genetic treasure trove of 
genomic sequences or a result of painstaking laboratory manipulation and selection, are 
desirous for their altered activity in various reaction conditions or for their altered 
substrate specificity.  
One example from our lab of such a well-characterized genetic part was the 
creation of a synthetically-evolved T7 RNA polymerase (Ellefson, et al. 2014). This 
synthetically-evolved T7 RNA polymerase, named G78-KIRV RNA polymerase (G78-
KIRV RNAP), was the product of a directed evolution scheme which shifted the 
promoter specificity of the wild-type T7 RNAP away from the wild-type sequence (GAC, 
in the -11 to -9 promoter specificity region) to CGG. In doing so, the G78-KIRV RNAP: 
CGG promoter pair became functionally orthogonal to the wild-type RNAP:GAC 
promoter pair in that each polymerase is uniquely active on its own promoter and inactive 
on the other promoter. These types of genetic parts are being used to create complex 
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genetic circuits in a variety of organisms (Brophy and Voigt 2014; Segall-Shapiro, et al. 
2014). These parts and circuits often operate outside of the biological contexts from 
which they originated and are thus rarely used to interrogate the evolution of whatever 
host genome provided the initial genetic part. Unfortunately, the lack of understanding of 
even the least complex and most modeled of organisms such as bacteriophages T7 and 
M13 make it difficult to predict exactly how any synthetically-evolved part will 
evolutionarily behave in any biological system (Kosuri, et al. 2007; Smeal, et al. 2017a, 
b). These same difficulties also plague circuits in general in that genetic stability and 
immutability are far from predictably designable or guaranteed. We realized the 
orthogonality of G78-KIRV T7 RNAP provided an excellent and unique opportunity to 
study the evolution of the bacteriophage T7 system from which it was originally derived 
within the context of a laboratory evolution experiment.  
In this study, we used the bacteriophage T7Δ1 populations previously adapted, or 
evolutionarily polarized, towards using the G78-KIRV RNAP in order to interrogate the 
totality of the T7 transcriptional apparatus by reinserting back, then further evolving, 
either the wild-type or the G78-KIRV RNAP into and together with the rest of the T7Δ1 
genomes. In doing so, we investigate interesting evolutionary questions such as how will 
the T7 transcriptional apparatus adapt and at what point has an organism, having gone 
through a period of adaption to a synthetically-evolved part, adapted enough such that it 
can be considered a distinct species. As such, we show how the use of laboratory 
evolutionary adaptation can complement rational design strategies while leading to 
interesting and unpredicted outcomes. 
 
Results 
Reinsertion of wild-type and G78-KIRV RNA polymerases into T7Δ1 genomes 
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In the previous chapter, we adapted T7Δ1, a bacteriophage T7 lacking its RNAP, 
for 100 passages on the synthetically-evolved G78-KIRV T7 RNAP, leading to the 
recovery of overall fitness (Figure 2.1A). Four lines evolved in parallel reached nearly 
the fitness of wild-type T7 phage.  However, the provision of the polymerase in trans (i.e. 
from a plasmid) was obviously an unnatural situation, and wished to determine whether 
and how the four evolved strains would accommodate reinsertion of either the wild-type 
T7 RNAP or the orthogonal G78-KIRV RNAP back into the phage (Figure 2.1B).  
To accomplish the reinsertion of either the wild-type or altered-specific RNAP 
into the evolved phage, plasmids were created in which the RNAP genes were flanked 
with 50-100 base pairs of homology to the phage genome, corresponding to the left and 
right flanking region around the Δ1 site. By passing the evolved strains in the presence of 
the plasmid, a small percentage should undergo homologous recombination and thereby 
allow further viral replication on BL21 E. coli cells that lack plasmids that express T7 
RNAP.  
We successfully recombined both the parental wild-type and the G78-KIRV 
RNAP into each of the genomes of the four evolved strains and then continued with 
another 50 passages on BL21 E. coli cells. All four of the evolved strains were able to 
successfully integrate both the wild-type and to G78-KIRV RNAP, respectively, into 
their genomes. Interestingly, even after repeated efforts, attempts to introduce G78-KIRV 
RNAP into the wild-type T7Δ1 progenitor would not produce viable phage. 
Promoter changes after reinsertion of the wild-type or G78-KIRV RNA 
polymerase into the bacteriophage genome 
Following passaging, the phage populations were sequenced via MiSeq 2x250bp 
pair end reads, 3.6x10
5
 reads per sample. When the G78-KIRV RNAP was reinserted into 
the four evolved lines, all of the mutated promoters from the initial evolutionary 
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adaptation were maintained (Figure 2.2). Interestingly, line 1 lost its ϕOL duplication 
while gaining a ϕ6.5 duplication, and line 2 lost its ϕ6.5 duplication (Figure 2.2). In 
contrast, when the wild-type RNAP was reinserted into the lines, five of the mutated 
promoters reverted back to the wild-type sequence:  the ϕ1.5 promoter in line 3, the ϕ6.5 
promoter in line 1, and the ϕOR promoter in lines 2, 3, and 4 (Figure 2.2). A number of 
duplications that arose during the original directed evolution experiment were lost: lines 1 
and 3 lost ϕOL duplications and lines 2 and 3 lost ϕ6.5 duplications (Figure 2.2). 
RNA polymerase stability after reinsertion and adaptation  
Once strains previously adapted to G78-KIRV RNAP had a chance to allow the 
polymerase sequence to change, two lines (1 and 2) incorporated an E756K mutation in 
the specificity loop (Table 2.1), while the other two lines (3 and 4) picked up an E222A 
mutation (100% fixed in line 3, 70% E222A/V in line 4, Table 2.1). The E222A 
substitution disrupts a salt bridge between E222 and R84, which appears to be otherwise 
unaltered as the RNAP goes through promoter initiation and elongation (Figure 2.3) 
(Cheetham and Steitz 1999; Tahirov, et al. 2002). Of the four lines that incorporated the 
wild-type T7 RNAP, no changes in the polymerase were observed (Table 2.1). 
In-vitro transcriptions with wild-type, G78-KIRV, G78-KIRV-E222A, and G78-
KIRV-E756K RNA polymerases on the unanticipated promoters found in the evolution 
The occurrence of the E222A or E756K mutations to the G78-KIRV RNAP 
together with the relative stasis of the promoters within the G78-KIRV-inserted lines 
justified further characterization of the G78-KIRV-E222A and G78-KIRV-E756K 
RNAPs. Throughout the initial 100 passages of adaption to G78-KIRV in trans, the 
anticipated GAG, CAG, and GGG as well as the unanticipated GCC, CCC, and AAG 
were the only promoter mutants to occur in more than one promoter in more than one 
strain, thus justifying further in-vitro characterization with the wild-type, G78-KIRV, 
 66 
G78-KIRV-E222A, and G78-KIRV-E756K RNAP variants. We chose the GCC, CCC, 
and AAG promoters to use for our in-vitro transcription activity assays because they were 
found in the G78-KIRV-phage populations but lost or diminished in the wild-type 
populations (Table 2.2) and because they, together with the wild-type (GAC) and cognate 
G78-KIRV promoter (CGG) provide relatively step-wise activity when transcribed by 
G78-KIRV RNAP (Figure 2.4). In the same manner as before, we purified the wild-type, 
G78-KIRV, G78-KIRV-E222A, and G78-KIRV-E756K RNAP mutants and determined 
their relative activity on the wild-type (GAC), G78-KIRV (CGG), and three 
unanticipated promoters (GCC, CCC, and AAG) (Figure 2.4). 
These data show that both the G78-KIRV-E222A and the G78-KIRV-E756K 
RNAP mutants found after passage in two each of the four lines after reinsertion of the 
G78-KIRV RNAP are generalists which have lost the specificity of the original G78-
KIRV RNAP. The E222A mutation, in spite of not existing in the RNAP specificity loop, 
seems to unexpectedly imbue the G78-KIRV with hyperactivity at or above wild-type 
activity on all of the five promoters tested. Additionally, these data show that the G78-
KIRV-E756K mutant is also a generalist with near-wild-type activity levels on the wild-
type promoter as well as a much higher activity on the orthogonal promoter (CGG) than 
that of wild-type RNAP. The G78-KIRV-E756K RNAP is also very active on the three 
unanticipated promoters. 
In-vivo activity assays confirm generalist activity of G78-KIRV-E222A and G78-
KIRV-E756K RNAP mutants 
We used a simple, anhydrous-tetracycline-inducible T7-promoter driven-GFP-
production circuit (Figures 2.5 and 2.6) in order to better understand and characterize the 
in-vivo behavior of the G78-KIRV-E222A and G78-KIRV-E756K RNAP mutants 
(Figure 2.7). We chose to use the wild-type T7 RNAP promoter (GAC, in the -11 to -9 
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promoter specificity region) and also, in contrast, a GGC variant because it provides 
relatively low in-vitro activity when used with the G78-KIRV RNAP, as seen in Figure 
1.1B in previous chapter. The wild-type and G78-KIRV RNAPs behaved as expected: the 
wild-type RNAP was extremely active on the wild-type promoter and moderately active 
on the GGC promoter whereas the G78-KIRV RNAP was had extremely low activity on 
either promoter (Figure 2.7). Interestingly, the G78-KIRV-E222A and G78-KIRV-
E756K RNAPs did indeed operate as generalists, both recovering activity on both 
promoters relative to G78-KIRV RNAP activity, with the G78-KIRV-E222A variant 
actually having higher activity on the GGC promoter versus the wild-type promoter.  
Of note, however, is that the G78-KIRV-E222A mutant, which had extremely 
high activity on all the promoters tested in the in-vitro activity assay, had a fraction of the 
in-vivo activity relative to the wild-type or G78-KIRV-E756K RNAPs. We presume that 
this is the result of spurious transcription by the G78-KIRV-E756K of the E. coli 
genome. We decided to test the E222A mutation independently of those in G78-KIRV 
(that is, the E222A mutation in the wild-type RNAP) and it indeed was enough to give 
near-wild-type promoter level of in-vivo activity on the GGC promoter, thus confirming 
the generalizability-enabling of the E222A mutation.       
 
Discussion  
The synthetically-derived G78-KIRV T7 RNAP and our previous evolutionary 
polarization of the T7Δ1 bacteriophage populations provided a unique opportunity to 
enforce an evolutionary bifurcation by respective RNAP reinsertion. In doing so, we 
hypothesized that placing these bacteriophages in these unique, parallel, and heretofore 
unexplored sequence space would lead to insights into the nature of transcriptional 
regulation and evolution in general.   
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The first insight unexpectedly came from the concurrence of: 1) the successful 
reinsertion of G78-KIRV RNAP into the evolutionary polarized populations with 2) the 
failed reinsertion of G78-KIRV RNAP back into the ancestor T7Δ1. This strongly 
suggests that the evolutionary adaptation through the serial passaging was essential to 
G78-KIRV RNAP being stably incorporated into the T7Δ1 phage genome. The ability to 
reinsert the wild-type T7 RNAP back into the evolved lines, however, was not 
unexpected: indeed in the initial evolutionary adaptation, only 4 or 5 of 16 promoters had 
mutated away from the wild-type sequence, leaving 10 or 11 of 16 wild-type promoters, 
presumably with the same transcriptional capacity as they normally would have in the 
ancestor T7Δ1 phage genome.  
The next series of insights came from the mutations which occurred after the 
reinsertion and adaption. Unlike our previous study, here we had no way to predict the 
nature by which mutations would occur in the promoter identities, abundances, or 
duplications, much less any mutations in the RNAPs. Phylogenetic analysis of T7 group 
phages suggests that, while T7-like promoters co-evolve with their respective RNAPs, 
they evolve at different rates (Chen and Schneider 2005). It has been hypothesized that as 
phages begin to diverge polymerases, there is a strong selective pressure on the entirety 
of the phage transcriptional apparatus (that is, both the polymerase and the promoters) to 
become distinct (Chen and Schneider 2005). Providing either the synthetic or wild-type 
RNAPs into these phage populations with a variety of promoter identities allowed us to 
experimentally rather than bioinformatically explore the relationship between promoter 
and RNAP co-evolution.  
After reinsertion of the wild-type RNAP, four otherwise fixed mutant promoters 
were reverted back to the canonical wild-type sequence (Figure 2.2, Table 2.2). Beyond 
these changes, the promoter identities stayed rather consistent as to what they were at the 
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passage 100 adaptation. These wild-type RNA-containing phages did, however, in four 
instances lose initial promoter duplications, likely reflecting their redundancy within the 
context of the wild-type RNAP. In the four lines passaged after reinsertion of the G78-
KIRV RNAP, there was no evidence of additional promoter mutation. Unlike those with 
the wild-type insertion, these lines did, however, maintain those mutated promoters that 
were there initially. Also in these lines, the pattern of changes in the duplications is a bit 
more muddled: two lines lost duplications and one line gained a promoter duplication. 
The pattern of promoter changes is only one half of the transcriptional system: the 
other half is the T7 RNAP itself. There were no mutations in the wild-type RNAP after it 
was reinserted and passaged beyond those necessary to allow viable RNAP expression 
(Table 2.1, and Figure 2.8). The G78-KIRV RNAP was, however, found to be mutated in 
all four lines (Table 2.1). Lines 1 and 2 had fixed in their populations an E756K 
mutation. This mutation, which occurs in the specificity loop of the T7 RNAP, reverts 
back one of the key mutations in G78-KIRV from a negatively charged glutamic acid to a 
positively charged arginine, which is more chemically similar to the wild-type residue 
lysine (Ellefson, et al. 2014). We noticed that an E222A mutant had fixed in line 3 in 
addition to an E222A/V mixed population reaching 70% of the population in line 4. This 
E222 residue, though far from the specificity loop, had previously been observed to 
enable an expanded range of T7 promoter-like sequences (Figure 2.3) (Ikeda, et al. 1993). 
We suspected that both the E756K as well as the E222A to the G78-KIRV RNAPs by the 
phage was enabling generalist polymerase functionality.  
In order to determine the exact nature of the E756K and E222A mutations in our 
phage populations we decided to do further in-vitro and in-vivo characterizations. In-vitro 
activity assays clearly show that both the G78-KIRV-E756K and the G78-KIRV-E222A 
RNAPs are generalists, with G78-KIRV-E222A in particular with at least 80% of wild-
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type level activity on all promoters tested (Figure 2.4). The in-vivo activity assays 
confirm that, the G78-KIRV-E756K and G78-KIRV-222A RNAPs enable activity on 
promoters that G78-KIRV alone is otherwise inactive (Figure 2.7). We decided to add the 
E222A mutation back into the wild-type RNAP (creating wild-type-E222A, Figure 2.7) 
which increased in-vivo activity on the GGC promoter, thus suggesting that E222A 
imbues T7 RNA polymerase with generalist activity and is extensible.   
 
Conclusion 
Overall, the bacteriophage populations altered the transcriptional apparatus such 
that the synthetic polymerase (rather than promoters) picked up subsequent mutations. 
Interestingly, both the further additions of either E756K or E222A mutations to G78-
KIRV resulted in the same outcome: the polymerases because generalists. This 
unexpected sequence divergence with phenotypic convergence is yet another example of 
the stochastic nature of evolutionary trajectories. This work is an example of how 
evolutionary optimization was essential for simple design implementation in even the 
most characterized of biological systems in that successful recombination of the G78-
KIRV was predicated on the previous adaptation to make the evolved populations. 
Furthermore, this work is an example of the power in enabling evolution to discover 
unexpected solutions: the creation of two new and distinct RNAP variants may be 
difficult to create outside of evolutionary-based schemes. Finally, our work raises the 
question of whether synthetic biology and directed evolution can be used for laboratory 
speciation events and the development of orthogonal viruses. A phage, having stably 
maintained the G78-KIRV RNAP while further mutating its promoters, could be 
considered its own species if it was unable to viably recombine, similar to bacteriophages 
T7 and T3. Future efforts into large-scale genome assembly and the current existence of 
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no less than six orthogonal T7 RNAPs may facilitate this laboratory speciation and the 
creation of orthogonal viruses (Meyer, et al. 2015).        
Materials and Methods 
Recombination of RNA polymerases back into T7Δ1 phage 
To reinsert either the wild-type or G78-KIRV RNAP back into the evolved 
lineages plasmids were created with approximately 50-100 base pairs flanking on each 
side of the RNAP corresponding to the left and right side of the T7Δ1 phage genome (see 
Figure 2.8). These plasmids were transformed into BL21-DE3 cells. Previously evolved 
T7Δ1 lines from the previous chapter were used to lyse these 10mLs of these cells 
induced with 1mM IPTG to allow phage propagation. To enrich for those which had 
successfully recombined either the wild-type or G78-KIRV RNAP into the phage 
genome all 10mLs of lysate was taken and added to 10mLs of BL21-Gold E. coli cells 
(Agilent) grown to an OD of 1 (approximately 10
8
 cells/mL). Successive passaging of 
10mLs from the previous flask into 10mLs of BL21-Gold cells eventually led to full lysis 
of the BL21-Gold cells, at which point 1uL (approximately 10
10
-10
11
 cfu/mL) of lysate 
was passaged. 
Phage passaging 
After recombination, 1uL of complete phage lysis (approximately 10
7
 phages) 
were added into 10mL BL21-Gold E. coli cells (Agilent) at a density of approximately 
108 cells/mL in 125mL Erlenmeyer flasks, which had previously been diluted from O/N 
stocks in 2xYT media and allowed to grow for one hour at 37° C. Flasks were shook at 
200 RPM at 37° C until complete lysis at which point 1mL of lysate was removed and 
mixed with 300uL of chloroform to halt any residual cell lysis and kill off any residual E. 
coli cells. At this point, 1uL of this lysate was then transferred to the next flask. Each 
cycle of 1uL transfer, infection, and lysis is considered one passage.   
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RNA polymerase purification 
RNAP variants were purified using the same protocol as mentioned in the 
previous chapter. Briefly, IPTG-inducible pQE plasmids containing each respective RNA 
polymerase variant were transformed into BL21-Gold E. coli cells (Agilent) and plated to 
isolate single colonies. These colonies are grown up overnight in their proper antibiotic 
and used to seed 1L flasks of 2xYT media (though 100mL cultures are adequate for non-
generalist RNA polymerases) which are grown at 37° C until reaching mid-log phase at 
which point 1mM of IPTG was added and the cells were grown O/N at 18°C then 
pelleted, frozen at -80° C O/N. Pellets were resuspended in the T7 buffer and subjected to 
Ni-NTA N-terminal 6x His column purification, as stated previously. The final, purified 
polymerases were each adjusted to 1mg/mL and stored at -20° C.         
Sequencing and analysis 
Similar to the methods in the previous chapter, 2x250 paired end read MiSeq runs 
with a coverage of at least 3.5x105 reads per phage were done and analyzed using breseq 
(Deatherage and Barrick 2014) as well as Geneious Version 7.1.9 (Kearse, et al. 2012) 
using the bacteriophage T7 genome (GenBank V01146.1) as reference.   
 
In-vitro transcriptions 
In-vitro transcriptions were carried out in a manner similar to elsewhere (Ellefson, 
et al. 2014). Briefly, 0.5uM DNA template (created from 2uM forward and reverse 
primer found in figure 2.9 after gel purification following primer extension) is transcribed 
in 10uL reactions using 0.5uM T7 RNAP in a 40mM Tris-HCl pH 7.0, 30mM MgCl2, 
6mM spermadine, and 10mM DTT buffer with 6mM each NTP and 0.17mg/mL DFHBI. 
Reactions were done at 37° C and readings at 469nm/501nm (excitation/emission) were 
taken every minute for two hours in a Tecan Safire monochromator.   
 73 
In-vivo GFP activity assays 
 pSK constructs containing each respective RNAP variant were transformed into 
BL21 E. coli cells after previous transformation with T7-promoter-driven GFP plasmids 
(pSK.201 or pSK.205, see Figures 2.5 and 2.6) and plated. Individual colonies were 
grown up O/N and diluted 1:100 into 1mL 2xYT media supplemented with 50ug/mL 
kanamycin and 50ug/mL ampicillin and grown for 3 hours. 50uLs of these cells were 
then diluted again into 50uL 2xYT, 50ug/mL kanamycin, 50ug/mL ampicillin, and 
anhydrous tetracycline (aTc) (to give final concentration of 2ng/mL or 20ng/mL) and put 
into clear Corning 96-well plates, covered with Breatheasy sealing cover, and read on a 
Tecan M200 plate reader which had a kinetic (orbital) shaking cycle of 2.5mm for 430 
seconds and took both an absorbance reading at 600nm and fluorescence readings at 
485nm/525nm (excitation/emission). All data uses biological triplicates.     
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Figures 
 
Figure 2.1: Passaging scheme and potentiality diagram 
 
 
Figure 2.1: Passaging scheme of previous work and outline of this work. (A, previous 
work) Four T7Δ1 phage populations were serially passaged 100 times on cells expressing 
the G78-KIRV RNAP in trans. Over the course of these passages, four phage replicate 
phage populations each mutated at least four of their promoters while almost completely 
regaining fitness thereby polarizing those populations towards the G78-KIRV RNAP. (B, 
this work) Those four passage 100 phage populations either had the wild-type or the G78-
KIRV RNAP, respectively, recombined into them and were passaged another 50 times. 
(Phage diagram) After recombination, the phage has the opportunity to continue to 
mutate its promoters in a potential evolutionary bifurcation event. (C, theoretical tradeoff 
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depiction) We hypothesized that there would be a mutually exclusive tradeoff in the 
evolution of transcriptional apparatus between further mutations in the polymerases or 
further mutations in the promoters.    
 
Figure 2.2: Promoter changes after reinsertion and passaging of wild-type or G78-KIRV 
RNAP  
 
Figure 2.2: Mapping location of all 16 T7 promoters in 40kB phage genome (green) in 
T7Δ1 (in A) and T7 with an RNAP in the Δ1 spot, colored yellow (in B). Mutated 
promoters are outlined in red boxes. Orange hexagon shows location of T7 terminator. In 
A, the promoters that changed in the four lines after 100 passages in each of the four lines 
(decreasing shades of red diamonds). In B, the promoters that changed in the four lines 
after 50 passages with either the wild-type (WT) or G78-KIRV RNAP were added back 
to the evolved (passage 100) strains. Asterisks in both represent the presence of promoter 
duplications in the sequencing data. 
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Table 2.1: RNA polymerase changes 
 
 
Table 2.1: Table displaying the mutations inside and outside the specificity loop in the 
wild-type or G78-KIRV RNAP inserted into each of the four lines after the 50 passages.  
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Table 2.2: Promoter mutations after reinsertion of each RNAP 
 
Table 2.2: List of promoters which mutated in each of the four lines after insertion of 
either wild-type or G78-KIRV RNAPs and 50 more passages.  
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Figure 2.3: Pymol rendering of the salt bridge between TEV protease E222 and R84 
 
Figure 2.3: Pymol rendering of E222 (in red) and R84 (in blue) in two different crystal 
structures of T7 RNA polymerase at various enzymatic points. In A, showing T7 RNAP 
initiation complex, E222A and R84 distance is 3.5 Å (PDB: 1QLN (Cheetham and Steitz 
1999)). In B, showing T7 RNAP elongation complex, E222A and R84 distance is 2.8 Å 
(PDB: 1H38 (Tahirov, et al. 2002)). The E222A mutation should break this salt bridge 
between E222 and R84.   
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Figure 2.4: In-vitro transcriptions  
 
 
Figure 2.4: In-vitro transcription activity assays with two starting RNAPs (wild-type and 
G78-KIRV) and the two generalist variants that emerged from the passaging (G78-
KIRV-E222A and G78-KIRV-E756K) on wild-type promoter (red), three intermediate 
promoters (purple) and the G78-KIRV promoter (blue). Values normalized to wild-type 
RNAP activity on wild-type (GAC) promoter. Error bars display standard error.  
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Figure 2.5: T7 RNAP induction plasmid map for in-vivo activity determination 
 
 
Figure 2.5: 
Plasmid map of pSK.101 construct used, in conjunction with pSK.201 or pSK.202, to 
determine in-vivo activity of each respective T7 RNAP variants. In this simple circuit, 
anhydrous tetracycline drives the expression of the T7 RNAP gene (in pSK.101 plasmid, 
above) which then will transcribe from the promoter variant on the pSK.201 or the 
pSK.205 plasmid, respectively, which eventually lead to the production of sfGFP.  
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Figure 2.6: GFP-plasmid map for in-vivo activity determination 
 
 
 
 
Figure 2.6: 
Plasmid map of pSK.201 or pSK.205 plasmids which, in conjunction with pSK.101 
plasmids, were used to determine in-vivo activity of each respective T7 RNAP variants. 
In this simple circuit, sfGFP gene (in plasmid map above) is transcribed by either the 
wild-type T7 promoter (TAATACGACTCACTATAG, as in the pSK.201 plasmid) or a 
low-activity variant promoter (TAATACGGCTCACTATAG, as in pSK.205 plasmid).  
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Figure 2.7: In-vivo GFP activity assays 
 
 
 
Figure 2.7: In-vivo GFP activity assays using wild-type, G78-KIRV, G78-KIRV-E222A, 
G78-KIRV-E756K, and WT-E222A polymerases on a high (GAC, in red) and low 
(GGC, in blue) strength T7 promoter-driven GFP at 130 minutes after 20ng/mL aTc 
induction. Error bars display standard error.  
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Figure 2.8: Design of recombination constructs to reinsert wild-type and G78-KIRV 
RNAPs back into T7Δ1 population genomes.  
 
Bacteriophage T7 will recombine with plasmids when provided with 50-100 base 
pairs of flanking homology around whatever insertion is desired up to a particular size 
overall phage genome size which otherwise becomes encumbering to genome packaging 
and capsid formation (Campbell, et al. 1978; Molineux 2006). For RNAP recombination 
into the T7Δ1 genomes we inserted  51 of 52 identical base pairs to the 5’ region 
immediately in front of the Δ1 deletion onto the 5’ end of each RNAP on pLUV-WT-
RNAP or pLUV-G78-RNAP (used in previous chapter):  
ATCTGCTGAGTGATAGACTCAAGGTCGCTCCTAGCGAGTGGCCTTTTTGATT 
This segment had a single base pair change A to T (underlined, above) which was 
included in order to facilitate reconstitution of a RNase III site which had been destroyed 
in the creation of the deletion in T7Δ1 while removing the possibility of spurious 
translation of later codons from an initiating methionine at “ATG”. Additionally, 50 
identical base pairs immediately downstream of the Δ1 deletion were also added to the 3’ 
end of each RNAP on pLUV-WT-RNAP or pLUV-G78-RNAP:  
GACCTTCTTCCGGTTAATACGACTCACTATAGGAGAACCTTAAGGTTTAA  
This region includes the T7 ϕ 1.1B promoter (underline, above) which, as part of 
the 50 base pairs of flanking homology, was essential to clone yet turned out to be 
problematic when cloning the into pLUV-WT-RNAP but not pLUV-G78-RNAP. We 
believe that this was the result of creating a runaway positive feedback loop whereas any 
wild-type RNAP made would initiate transcription at the ϕ 1.1B promoter and 
transcription of more RNAP in an “autogene”-like circuit, a circuit which quickly 
succumbs to error catastrophe in-vitro (Davidson, et al. 2012) and in-vivo (personal 
observations).  
As such, we isolated a mutant pLUV-Flank-WT-RNAP with a single G to T 
mutation which turned the third amino acid of the His-tagged wild-type RNAP from 
coding for a GGA (Gly) to TGA (stop). This allowed for recombination of the wild-type 
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RNAP back into the evolved lines, which all experienced a C to T mutation converting 
ACG (T3, using no-His tag wild-type T7 RNAP numbering convention) to ATG (Met). 
This effectively undoes the initial TGA (stop) mutation and allows viable wild-type T7 
RNAP (albeit without a His-tag) to be expressed from the phage genome.    
 
Table 2.3: Primers used to create the in-vitro templates 
 
Table 2.3: Primers used to create the in-vitro templates 
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Chapter 3: Construction, Exploration, and Optimization of a Designed T7 Life-
Cycling System Reliant on Proteases 
 
Abstract 
Proteases are a biotechnologically, medically, and economically important class 
of biomolecules which extend across the three domains of life. This work describes the 
initial attempts to devise a bacteriophage T7Δ1-based system, as well as the subsequent 
adoption and optimization of a bacteriophage T7Δ10-based system, constructed in order 
to facilitate the essential genomic incorporation and use of a foreign protease such that 
bacteriophage replication is strictly dependent on protease activity. In doing so, work into 
enhancing the speed of the tobacco etch virus protease (TEV protease) and its plasticity 
regarding non-canonical target substrate cleavage specificity is explored. Furthermore, in 
addition to the creation of a T7-TEV bacteriophage-protease-based pair reliant on 
cleavage on its canonical target substrate for viable bacteriophage life cycling, the 
creation of a T7-rhinovirus-14 3C protease (3C protease) reliant on its protease activity is 
also reported. Together, it is shown that these designed T7-TEV and T7-3C phage-
protease chimeric viruses show orthogonality which in effect enables selective cell killing 
of E. coli cells dependent on which protease-target they have. The potential use of these 
E. coli cell-specific targeting viruses, together with the overall deficiencies, power, and 
potential of this T7-protease system, are discussed.    
 
Introduction 
Proteases, a class of protein enzymes that cleave other proteins, make up 2% of 
the human genome (notwithstanding those in other prokaryotic and eukaryotic species) 
and are important for therapeutic, industrial, and biotechnological applications (Li, et al. 
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2013). Therapeutic use of protease inhibitors represents a multi-billion dollar per year 
market (Turk 2006). As such, proteases are an attractive target for protein engineering. In 
spite of this widespread applicability, rational design and directed evolution of proteases 
has been difficult on account of toxicity issues inside of whatever cellular chassis is used 
to produce them (Pogson, et al. 2009).  
One strategy developed to get around this issue has been to express the protease 
for export to the surface of either E. coli or yeast cells where their activity is linked to a 
sortable output, such as fluorescence (Varadarajan, et al. 2008; Yi, et al. 2013). Such 
strategies, however, are limiting: proteases may not function when placed on the 
membrane, some may act differently outside of the cellular context based upon 
differences such as pH, and said strategies require elaborate and potentially noisy 
methods such as antibody tagging and FACS sorting. Additionally, these strategies have 
limited dynamic range such that it may be difficult to discern between a “good” variant 
and a “great” variant. 
As we began working on the previous T7Δ1 evolution projects mentioned in the 
previous chapters, we realized that a T7-based evolution system could be created in 
which life cycling could be made reliant on protease activity. This system offers 
advantages over surface display-based systems mentioned above: the protease would 
work in the context of the cell itself (which is not likely to suffer the same toxicity issues 
on account of being destroyed by the replicating bacteriophage). Inspired by Phage-
Assisted Continuous Evolution,  we had anticipated that the speed of replication of 
bacteriophage T7 (faster than PCR), its rapid rate of phage amplification (a single 
bacteriophage T7 could lyse the world‟s oceans-worth of mid-log E. coli cells in seven 
hours), and intense theoretical sampling of sequence space via mutation (a fully-lysed 
1mL E. coli culture produces a phage population which mutationally samples each 
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nucleotide position 250 times) would lead to an amenable continuous evolution system 
(Appendix). Unlike PACE-based evolution systems, however, a T7-based evolution 
system would require no elaborate steps: all that is required would be to passage the 
bacteriophage on a series of flasks with target cells (Esvelt, et al. 2011).   
There are additional advantages to a T7-based evolution system to specifically 
evolve proteases. A T7-based system is theoretically easily adaptable to use with multiple 
variants proteases/protease targets by simple swapping out the protease into the genome 
and/or any target protease cleavage sight you want to try to target. Additionally, this 
directed evolution system could be easily adapted to other proteases, the only constraint 
being that they would need to be able to be expressed and function in the E. coli 
cytoplasm. It is already known that in addition to TEV, the HIV protease, the Hepatitis C 
protease, and the Human Rhinovirus 3C protease all can be expressed and function in E. 
coli (Dickinson, et al. 2014). 
 
Selection of TEV protease and Initial Efforts to Use T7Δ1 strain 
TEV protease was initially chosen as the first protease to use in such a system for 
a variety of reasons. TEV protease, a 27kDa cysteine protease originally from the 
genome of the Tobacco Etch Virus, can successfully be expressed in E. coli, function in-
vivo, and can be purified from E. coli for in-vitro assaying (Parks, et al. 1995; Wei, et al. 
2012). TEV protease has also been extensively subjected to engineering and assaying for 
various purposes using a variety of techniques: solubility optimization, using a whole-cell 
fluorescence assays; substrate profiling, using antibiotic resistance or bacterial 
display/flow cytometry sorting; and even increasing substrate tolerance or altering 
substrate specificity, using S. cerevisiae auxotrophy-dependent pigmentation assay or the 
S. cerevisiae-based Yeast ER Sequestration Screening system (Kostallas and Samuelson 
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2010; Renicke, et al. 2013; Sandersjoo, et al. 2017; Sandersjoo, et al. 2014; van den Berg, 
et al. 2006; Yi, et al. 2013).   
Additionally, the specificity of the TEV protease has been extensively 
characterized in-vitro, in-vivo and has been aided by the solving of crystal structures of 
TEV mutants bound to target substrates (Dougherty, et al. 1989; Phan, et al. 2002). 
Indeed, the exquisite specificity of the TEV protease towards its 7 amino acid canonical 
cleavage site, ENLYFQ/S, has led to its extensive use as a biotechnological tool for in-
vivo and in-vitro cleavage of fusion proteins (Phan, et al. 2002; Shih, et al. 2005). 
Interestingly, in addition to its canonical ENLYFQ/S, the TEV protease has retained 
intramolecular proteolytic activity on GHKVFM/S, which is the 213th to 219th amino 
acid itself, in spite of being so different than the canonical cleavage site (Figure 3.1) 
(Phan, et al. 2002). The crystal structure of the TEV protease together with its substrate 
provides structural clues which can inform the nature of the interactions between the two 
and thus inform which residues are fungible (Figure 3.2).     
Because no crystal structure has been generated using the self-cleavage site, only 
those structures with the canonical site were used to understand the nature of the 
specificity of each residue of the canonical substrate. From these structures and 
biochemical studies, it has been determined that the P6, P3, P1, and to a lesser degree P1‟ 
are the main drivers of specificity determination of the TEV protease for its canonical 
substrate (Dougherty, et al. 1989; Phan, et al. 2002). In particular, the Glu in P6, the Gln 
in P1, and the Ser in P1‟ were identified as the locations by which alterations in 
specificity could be made and then exploited in order to drive evolution of the TEV 
protease in this system towards that of this new and hopefully orthogonally targeting, 
substrate. Indeed, one of the ultimate goals to test the limits of this system as a directed 
evolution platform to generate multiple orthogonal protease:substrate pairs.  
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Before reaching for that brass ring, though, there was lower hanging fruit to 
initially go after. TEV protease is an exceptionally slow enzyme, with a kcat of 0.16 s
-1
 at 
30°C (Kapust, et al. 2001). This leads many who use it biotechnologically to use an 
overnight digestion, usually at 4°C, a temperature chosen in order to preserve the 
integrity of the desired overexpressed protein to the further detriment of TEV activity. 
Based on our previous work exploring T7Δ1, we believed it could be used to create a 
system which would link genotype (in this case, TEV protease genomically integrated 
into the T7Δ1 locus) to phenotype (in this case, speed of proteolytic activity) by driving 
creation of something functional that would differentially allow phage life cycling. 
Because we were using the T7Δ1 system, an obvious way to constrain this phage system 
and allow differential life cycling was the use of a plasmid-driven T7 RNA polymerase. 
As noted in the previous chapters, T7Δ1 will not replicate in the absence of T7 RNAP. 
As such, we decided to create fusions of split T7 RNAP with E. coli beta-glucuronidase 
(GUS) with the canonical TEV substrate as linker(s), aspiring to find a variant fusion 
protein which lacked T7 RNA polymerase activity without cleavage by TEV yet retained 
activity when TEV freed the fusion proteins. Our lab‟s previous work and experience 
with T7 RNA polymerase in addition to GUS, showed that T7 RNA polymerase was 
viable as a split protein and that the 614 amino acid GUS protein would be a viable 
choice for either N-terminus or C-terminus fusion (Flores and Ellington 2002; Segall-
Shapiro, et al. 2014).  
Three plasmids were created with various fusion proteins, all based on the pLUV 
chasis, by which inducible expression was driven by the LacUV5 promoter. The first 
(pLUV-alpha-GUS-beta) had the first 601 base pairs of the T7 RNAP: TEV cleavage 
site: GUS: TEV cleavage site: rest of T7 RNAP. The second (pLUV-beta-GUS) had, as 
before, the first 601 base pairs of the T7 RNAP: TEV cleavage site: GUS while allowing 
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the 601:883 amino acid piece of the T7 RNAP to be independently expressed from 
another LacUV5 promoter. The third (pLUV-GUS-beta) had GUS: TEV cleavage site: 
first 601 base pairs of the T7 RNAP then, as the previous construct, the 601:883 amino 
acid piece of the T7 RNAP was allowed to be independently expressed from another 
LacUV5 promoter. With these three constructs, each together with a separate plasmid 
with an anhydrous tetracycline-inducible TEV protease, we were able to determine the 
relative ability of each to support viable T7Δ1 phage replication in BL21 E. coli cells 
(Table 3.1).  
The lysis assays clearly show that when the RNAP-GUS fusions are expressed 
together with TEV protease the T7Δ1 phage replicate at a faster rate than in any other 
circumstance. It is worth noting that the alpha-GUS-beta fusion expressing construct, 
where both pieces of the split T7 RNA polymerase are fused between two canonical TEV 
cleavage sites on either end of GUS, took the longest of the three constructs to lyse. 
Because of the need for two cleavage events instead of one (in addition to the rather large 
size of the alpha-GUS-beta polyprotein and any relative decrease in protein expression 
with this construct relative to the other two) this result strongly suggests the TEV 
expression is responsible for cleavage and thus ultimately playing the role in which we 
expect it to in this system. Although this is promising, the decrease in OD600 (and, by 
proxy, the successful lysis by the T7Δ1 phage of the E. coli cells) in the T7Δ1 phage 
infected -tet/+lac induced cells of both those harboring the beta-GUS and GUS-beta 
constructs was worrisome: this result, taken together with the other OD600 data, indirectly 
suggests that these constructs, when highly expressed, still allow for some partial T7 
RNA polymerase activity and therefore successful the T7Δ1 phage replication.  
In spite of this partial T7 RNA polymerase activity and therefore delayed (albeit 
successful) T7Δ1 phage life cycling, a construct was designed based upon the pLUV-
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Flank-wild-type-RNAP plasmid used in the previous chapter to reinsert the T7 RNA 
polymerase back into the evolved the T7Δ1 phage lines. This plasmid, pLUV-Flank-
TEV, was built to completely substitute out the RNA polymerase and contain in its place 
the TEV protease S219P mutant, which is self-cleavage resistant (Kapust, et al. 2001). 
This construct was used, in 1mM IPTG induced BL21-DE3 E. coli cells, in an attempt to 
stimulate recombination of the TEV protease into the Δ1 locus of the T7Δ1 phage and 
thus enable phage replication. These attempts to enrich for potentially recombined now 
“T7-TEV” phage on all three of the GUS-fusion plasmid populations (after multiple 
attempts, multiple rounds of passaging on pLUV-Flank-TEV in the hopes of increased 
recombination, and even after the use of multiple T7 growth strategies such as plates 
versus liquid culture) led to the same conclusion: no recombinants were found. Though 
this design strategy was shown to not work, it did show that split T7 RNA polymerase 
could be constrained by GUS fusion within the activity required of T7Δ1 phage in such a 
way to at least delay T7Δ1 phage replication. To reach the next step of protease-
containing T7 phage in which life cycling is dependent on externally programmed 
stimuli, a new design modality was needed.   
 
Switching to a T7Δ10 system 
At this point, at the suggestion of Ian Molineux, we abandoned the T7Δ1 phage 
system in favor of a T7Δ10 phage system. In such a T7Δ10 system, the major capsid 
protein 10A (from T7 gene 10) is exploited in order to link the phenotype (the function of 
the protease) with its genotype (its DNA code). Gene 10 actually codes for two different 
versions of the major capsid protein, 10A and 10B, where the 10B protein, though not 
essential, gets produced at about 10% of the frequency of the 10A protein as a -1 
translational shift at the 3‟ end of 10A (Molineux 2006). Henceforth, all references to the 
 92 
major capsid protein will refer to the 10A gene product.  415 of these major capsid 
proteins assemble to make one of the icosahedral capsids of the T7 virus and its 
production is the limiting step of late T7 replication (Guo, et al. 2014). T7Δ10 strains 
(where the major capsid protein is deleted) will not lyse cells and complete life cycling 
unless it is complemented in trans with the gene 10 expressed from a plasmid. As before, 
the design entailed the creation a fusion protein between the T7 major capsid protein and 
E. coli theoredoxin A (TrxA) linked by a protease site such that the fusion protein will 
not make viable bacteriophage without cleavage of the fusion protein.  
Fusions with the T7 major capsid protein have already been demonstrated for use 
in phage display such that it is known that it can tolerate up to 50 amino acid fusion to its 
C-terminus and still be functional (Novagen 2014). TrxA is a 110 amino acid protein 
which has been used previously as N and C terminal fusion protein expression system to 
circumvent aggregation in E. coli inclusion bodies and also presented an intriguing 
possibility as adding yet another selective pressure, as TrxA is essential to bacteriophage 
T7 life cycling (LaVallie, et al. 1993; Molineux 2006). Conceptually, to run this 
system/selection, our non-functional major capsid protein fusions were to be expressed, 
as before, from a Lac inducible promoter (LacUV5) from a plasmid (pLUV) in target 
BL21 E. coli cells. T7Δ10 bacteriophages with protease variants inserted into their 
genomes targeting the protease site linker in the fusion protein were then to be added to 
these target cells. The viruses with functional proteases will propagate and those that do 
not will not. A library of protease variants could theoretically be screened against any 
number of protease site linkers in the major capsid protein simply by swapping out one 
linker for another (Figure 3.3).  
As before, two fusion proteins were designed (a gene 10: TEV cleavage site: 
TrxA fusion and a TrxA: TEV cleavage site: gene 10 fusion) which, together with a gene 
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10 only control, was subjected to the same plasmid-based TEV and fusion protein 
expression assay to determine to what extent these constructs could support successful 
T7Δ10 life cycling (Table 3.2). All of the cells harboring the gene 10 only control 
construct and infected with T7Δ10 lysed, which is not surprising given the leakiness of 
the lacUV5 promoter. In contrast, the gene 10-TrxA containing cells, even with high 
expression of both the protease and fusion protein did not seem to lyse. Finally, those 
cells containing the TrxA-gene10 construct only lysed when the protease was highly 
expressed. The fact that both the +tet/-lac induced cells and the +tet/+lac induced cells 
both lysed, at first blush, may appear to be worrisome: this worry, however, is needless, 
as it was shown with the gene 10 only control that the lacUV5 promoter is leaky. As 
such, the main takeaway is that TEV protease expression was necessary to allow for 
successful T7Δ10 life cycling.  
This led, as before, to attempt to reinsert the TEV S219P protease into the Δ10 
locus of T7 through the creation of pPOS-Flank-TEV, a p15A origin Cm resistant 
plasmid which had 140 bp and 64bp of flanking homology on the left and right side, 
respectively, of the Δ10 locus. Most importantly, the 140bp of flanking homology on the 
left side of the pPOS-Flank-TEV contained a T7 promoter which should enable 
production of TEV protease by any infecting T7Δ10 in a manner similar to pAR5403, a 
pBR322 origin, Amp resistant plasmid containing a T7 promoter-driven major capsid 
protein which enables complementation of T7Δ10 (in a similar manner as BL21-DE3 
strain was used to complement T7Δ1). As before, a vast array of techniques was 
employed in an attempt to enrich for T7-TEV phage. Finally, one of them worked: 
T7Δ10 were passaged for 5 passages on BL21 E. coli cells which contained both the 
pPOS-Flank-TEV plasmid and a pLUV-T7pro-TrxA-TEV-site-gene-10 which was 
identical to the pLUV-T7pro-TrxA-TEV-site-gene-10 plasmid except the LacUV5 
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promoter was swapped for a T7 promoter. The reinsertion was confirmed via PCR, 
population sequencing, as well as individual phage isolate sequencing.  
The reasoning behind successful insertion of the protease into T7Δ10 relative to 
the failure of the same into T7Δ1 was not determined. Speculating, it would seem as if 
the T7Δ10 system was controlled by the protease more than the T7Δ1 was. This 
increased dependency or constraint upon the system, together with the use of T7 
promoter-driven transcription of both proteases and fusions, was apparently enough for 
enrichment. It was highly fortuitous that the 140bp of left flanking homology in front of 
the TEV in the pPOS-Flank-TEV plasmid enabled both recombination as well as 
expression of the TEV protease. Finally, although noticed later, it would seem as if the 
plasmid copy number of the plasmid on which flanking homology to recombine into the 
T7 genome has a direct effect on the efficiency of this relatively low efficiency event. 
The efficiency of plating after recombination into T7 from a pUC plasmid (mutated 
pMB1 origin, copy number ~500-700) is roughly 10
-5
 versus roughly 10
-7
 on the pPOS 
plasmid (p15A origin, copy number 10-12) (Kiro, et al. 2014). As such, at a certain point, 
the system was switched from using the pPOS plasmid to a pUC plasmid for protease 
recombination.   
 
Wild-type TEV drift mutations and TEV-Fast explorations 
Isolates of the initial TEV-S219P mutant protease in T7 bacteriophage were 
plated on 1mM induced pLUV-TrxA-TEV-site-gene-10 cells, and single phages were 
isolated and grown, from which each respective TEV protease was PCR amplified and 
sequenced. All ten of these isolates were the original TEV-S219P inserted into the T7 
genome. One of these isolates was then used to passage, in triplicate, on 1mM induced 
pLUV-TrxA-TEV-site-gene-10 cells with a transfer volume of 1uL, giving an 
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approximate MOI of 0.1 for 10 passages. Ten phages from each of the three populations 
were isolated and their TEV proteases were PCR amplified and sequenced (Table 3.3). 
By passage 10, all of the thirty isolated bacteriophages had a picked up a P219S mutation 
which functionally mutates the proline back to the wild-type serine residue and thus 
renders the protease susceptible to self-cleavage. This in and of itself would not be of 
interest except for the fact that the wild-type (219S) TEV has a kcat of 0.16 s
-1
 and kcat 
/Km of 2.62 mM
-1
 s
-1
  whereas the S219P TEV has a kcat of 0.09 s-1 and kcat /Km of 
1.36 mM
-1
 s
-1
  (Kapust, et al. 2001). In effect, in the course of only 10 passages, the 
bacteriophage had mutated its TEV into a faster, more efficient TEV protease. The 
bacteriophages also all picked up an N177T mutation which, by analysis of the TEV 
crystal structure, interacts with the P6 Glu of the TEV substrate and is thus hypothesized 
to stabilize the binding of TEV protease to its substrate (Figure 3.4).  
Encouraged by this, another series of passages were done with the original 
S219P-TEV-containing phage over pLUV-TrxA-TEV-site-gene-10 cells which also 
contained a Flanked (i.e. flanked with homology to the phage to enable recombination) 
TEV-Fast protein. “TEV-Fast” is the moniker given to a G79E, T173A, and S219V TEV 
mutant which emerged from the yeast ER sequestration screening (YESS). TEV-Fast has 
the fastest published kcat of any TEV protease at 0.30 s
-1
 (Yi, et al. 2013). We wanted to 
see if the S219P-TEV bacteriophage, a small fraction of which would recombine in the 
TEV-Fast, would get outcompeted by that small fraction of now TEV-Fast-containing 
phage. From screening 30 isolates there was no evidence of TEV-Fast although the 
N177T mutation was picked up by 22/30 phages and the P219S reversion occurred in all 
30 bacteriophages (Table 3.4). 
We then decided to isolate S219V-TEV and TEV-Fast recombinant T7 
bacteriophage and passage them. The S219V mutant, another of the cleavage-resistant 
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variants, is the second fastest published TEV protease after TEV-Fast, with a kcat of 0.19 
s
-1
 (Kapust, et al. 2001). After 10 passages on 1mM induced pLUV-TrxA-TEV-site-gene-
10 cells, no mutations occurred in either population. In an effort to both enrich for 
protease activity as well as for mutants the concentration of IPTG used to induce the 
pLUV-TrxA-TEV-site-gene-10 cells was decreased to 100uM and the MOI was reduced 
to 0.01. After another 10 passages, all ten of isolates from the S219V population had a 
N177I mutation and 8/10 had an R51H mutation (Table 3.5). Ten of ten isolates from the 
TEV-Fast population had picked up the N177T mutation and one had a S219G mutation 
(Table 3.6). Taken together within the context of the previous mutation data, these data 
suggest that mutating the N177 residue (specifically to N177T) is favorable and 
presumably leads to an increased speed of TEV protease.   
 It is relatively easy to characterize cell lysis time by bacteriophage T7 through the 
use of a plate reader. Cell lysis time (together with burst size) is a major contributor 
towards overall bacteriophage T7 fitness. As such (using the methods described in 
previous chapters), the cell lysis times of various TEV-phage populations at two different 
induction strengths were determined (Figures 3.5 and 3.6). These data show very little 
difference in lysis time among all of the T7-TEV phage populations at 1mM IPTG 
induction (Figure 3.5). These data also show that, when the inducer concentration is 
lowered to 10uM IPTG, the later passaged phage populations (that is, passage 10 vs. 
passage 1 for the S219P phage, passage 20 vs. passage 1 for S219V phage, and passage 
20 vs. passage 1 for the TEV-Fast phage, respectively) all lyse at a faster rate than their 
ancestor phages (Figure 3.6). This suggests that the mutations in the TEV proteases at 
these later passages, mutations elsewhere in the T7 genomes, or both, are responsible for 
the rapid decrease in cell lysis time. As no next-generation sequencing was done in order 
to determine any T7 genome mutations outside of the TEV protease gene, the answer to 
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this question is currently unknown. Though it is tempting to speculate that the addition of 
N177T independently in all of the bacteriophage populations has led to faster proteolytic 
activity by each TEV protease further kinetic characterization  would be needed. Having 
learned a bit about this novel T7 life cycling system, and with a TEV-S219V N177T 
mutant in hand, we decided to press on towards exploring whether the T7-TEV phage 
system could be used to expand substrate specificity and, ultimately, lead to 
orthogonally-acting proteases.        
 
TEV substrate specificity expansion and orthogonality explorations 
Somewhat in parallel with the TEV kinetic explorations above the S219V, N177T 
TEV-containing bacteriophage T7 evolved after 20 passages was subjected to E. coli 
cells containing plasmids encoding for TrxA-gene 10 fusion beyond the canonical TEV 
substrate (ENLYFQ/S). Specifically, the S219V, N177T TEV-containing bacteriophage 
were subjected to four non-canonical TEV target populations: EΔW, in the P6 target 
substrate locus (WNLYFQ/S), YΔE in the P3 target substrate locus (ENLEFQ/S), YΔH, 
also in the P3 target substrate locus (ENLHFQ/S), and QΔH in the P1 target substrate 
locus (ENLYFH/S). All of these sites (in the P6, P3, and P1 substrate loci) were chosen 
because of their importance for their TEV protease specificity determinants. The QΔH 
population, in particular, was chosen on account of the preceding success with its use in 
the YESS system and nominally served as a basis for comparison between the YESS 
system and this novel protease evolution methodology (Yi, et al. 2013). Each of the 
populations, save the QΔH-adapted population, was adapted in the following order of 
apparent increase in stringency: 10 passage on 1mM induced target at an MOI of 0.1, 
followed by 10 passages on 1mM induced target at an MOI of 0.01, and finally 10 further 
passages on 1uM induced target at an MOI of 0.01, giving overall 30 passages on each 
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non-canonical TEV substrate (Figure 3.7). The QΔH-adapted population was not able to 
lyse target cells at 1uM IPTG induction and thus the series of passages were omitted. 
Lysis time with these evolved populations was then determined on E. coli cells harboring 
each of their own adapted TEV substrate target, the other non-canonical TEV substrate 
targets, as well as the canonical TEV substrate target (Figures 3.8-3.12).  
The ancestor N177T, S219V TEV-containing phage (before the 30 passages on 
the non-canonical TEV substrate target) lysed the canonical TEV substrate target the 
fastest, followed by the EΔW target substrate locus (WNLYFQ/S), then the YΔH target 
substrate locus (ENLHFQ/S), and finally the YΔE target substrate locus (ENLEFQ/S) 
and the QΔH substrate locus (ENLYFH/S), which shown no signs of lysis in this assay 
(Figure 3.8). The adapted populations, however, lysed each of their respective adapted-to 
non-canonical TEV substrate targets at or nearly within standard deviation as quickly as 
they lysed the canonical TEV substrate target (Figures 3.9-3.12). These populations also 
lysed each of the non-canonical TEV substrate target-containing cells differentially. In 
particular: 1) the EΔW adapted population lysed the YΔH target cells within deviation of 
its own target while lysing the YΔE and QΔH cells at a slower rate, 2) the YΔH adapted 
population lysed both the YΔE and EΔW nearly as quickly as itself while lysing the QΔH 
cells at a slower rate, 3) the YΔE adapted population lysed both the YΔE and EΔW 
nearly as quickly as itself while lysing the QΔH cells at a slower rate, and 4) the QΔH 
adapted population lysed, in order, the YΔE, EΔW, and YΔH at a slower rate than it or 
the canonical TEV substrate (Figures 3.9-3.12).   
Isolates from each of these four non-canonical TEV substrate adapted populations 
were sequenced (Table 3.7). Although each isolate has quite the variety of further 
mutations beyond the original S219V and N177T ancestor (ranging from at the minimum 
three and at the maximum five additional non-synonymous mutations) strikingly none of 
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the four non-canonical TEV substrate adapted populations have any mutations which 
they and they alone possess (Table 3.7). This strongly suggests that most of these 
mutations are generally enabling, that is, allowing either generalist TEV protease activity 
or allowing enhanced protein expression and translation. Yet an apparent incongruity 
exists: how do these sequence heterogeneous phage populations lead to differential speed 
of lysis seen in the lysis assays? One potential explanation is that the apparent 
heterogeneity among each adapted population (in the apparent absence of exclusivity of 
any mutations between each population) is specifically tuned in relation to each other 
such that, on the whole, the population gains the observed differential lysis. Another 
possibility is that the rare variants within each population are responsible for these 
differential lysis timing. No work followed in order to tease out these differences, 
although in hindsight it would be of interest to determine what further evolutionary 
adaptation would occur with single phage isolates of some of the relatively rare mutations 
or mutational combination phages. Finally, it is not impossible that adaptation in the rest 
of the bacteriophage T7 genome beyond the TEV protease is responsible for the 
differential lysis times. Though theoretically possible, the strong selective pressure on the 
TEV protease activity itself, born out by its rapid accumulation of mutations, makes this 
unlikely.     
Interestingly, the EΔW, YΔE, and YΔH adapted populations all lysed the QΔH 
containing target cells the slowest. This suggested that there entailed a potential degree of 
orthogonality between these populations. As such, an EΔW, QΔH (WNLYFH/S) double 
mutant TEV target substrate was created. After a multitude of efforts using both EΔW 
and QΔH adapted populations (including, but not limited to, passaging on gradually 
increasing double mutant cell population), there was no successful lysis on this double 
mutant. As such, it was determined that, though interesting, these gradual steps towards 
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altered specificity would not ultimately be productive as far as evolving an orthogonally 
acting TEV protease from its wild-type ancestor and that other alternatives should be 
pursued.   
 
Rhinovirus 3C and orthogonality between T7-TEV and T7-3C phages 
Though the path forward to actually evolving a panel of orthogonally-acting TEV 
proteases via this T7-based system was limited there was still the potential to use new 
proteases. The rhinovirus-14 3C protease was chosen after using TEV as the initial proof-
of-concept. Rhinovirus 3C protease has many of the same advantages for use in the T7 
system that TEV protease does: it can be functionally expressed in E. coli, its specificity 
has been investigated, and it has a published crystal structure (Cordingley, et al. 1990; 
Cordingley, et al. 1989; Matthews, et al. 1994). Rhinovirus 3C protease, a cysteine 
protease with exquisite specificity for recognizing and cleaving LEVLFQ/GP, has been 
used biotechnologically to cleavage fusion proteins and also as a target of chemical 
inhibitors seeking to provide antiviral activity against rhinovirus life-cycling in humans 
(Binford, et al. 2007; Wang and Johnson 2001).  
Rhinovirus 3C protease was cloned and expressed in trans (i.e. from a plasmid) 
along with the TrxA-3C target site-gene 10 fusion protein as TEV was before in order to 
determine whether protease activity could enable T7Δ10 life cycling (Table 3.8 and 
Figure 3.13). The successful lysis when only the protease and target fusion constructs 
were highly expressed was encouraging and led to the cloning of the 3C protease into a 
pUC vector with the flanking regions around the T7Δ10 locus. Recombination of the 3C 
protease into the bacteriophage T7, now generating T7-3C phage, was successful. Efforts 
to passage this T7-3C phage on both T7 promoter and LacUV5-driven 3C target 
constructs for 30 passages resulted in the accumulation of no mutations to the 3C 
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protease. This could be a result of the 3C protease acting as a higher turnover enzyme 
(with a kcat of 3.4 s
-1
) relative to TEV protease (kcat of 0.16 s
-1
) (Kapust, et al. 2001; Wang 
and Johnson 2001).  
Instead of jumping into pursuing the evolution of rhinovirus 3C protease variants 
towards non-canonical 3C target cleavage sites it was decided to determine the relative 
orthogonality of the T7-TEV and T7-3C proteases in the context of T7-protease life 
cycing. Ideally, the T7-TEV phage would only lyse cells containing its ENLYFQ/S 
canonical target substrate with T7-3C phage only lysing cells containing its LEVLFQ/GP 
canonical target substrate (Figure 3.14). Lysis curves with each respective T7-TEV and 
T7-3C phage on the TEV and 3C target substrate cells clearly show this orthogonality 
(Figures 3.15-3.17). Further work, using tubes of mixes of TEV and 3C target substrate 
cells subjected to the T7-TEV phage, T7-3C phage, or both, at various concentrations of 
phage, cell amounts, and inducer, was not able to reach the point of differential lysis, that 
is, the point at which which only one type of non-targeted cell population was able to 
survive while the other, targeted type would die. This is to be expected in a static mixture 
of two types of targeted cells: as one gets targeted and lysed, it releases the approximate 
burst size of T7 (260 phages/infected cell) which can then infect en masse and kill the 
non-target E. coli cells by membrane destabilization, genomic destruction, or perhaps 
even basal protease activity on the non-target substrate (De Paepe and Taddei 2006). 
Differential cell killing via the combination of T7-proteases and target-containing cells is 
anticipated to be successful not in a static test-tube environment but rather in a 
chemostatic environment where viruses get washed out instead of building up in this 
system (for that matter, so could the efforts towards evolving protease variants towards 
non-canonical targets) (Bull, et al. 2006). Said efforts, if successful and parameterized, 
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may ultimately enable the use of these T7-proteases for selective E. coli cell killing in 
rodent or human gut model systems (Bull and Gill 2014). 
 
Other efforts to expand this T7-protease system 
The realization that this T7-protease system could be used for other purposes both 
beyond evolving proteases towards non-canonical target cleavage sites and beyond 
selective cell killing did not go unrecognized. Similar to evolution of protease-drug 
resistance using PACE, this T7-protease system could also be used to discover which 
mutations lead to resistance to protease inhibitors (Dickinson, et al. 2014). As such, the 
T7-3C phage was screened against E. coli cells which had been treated with various 
concentrations up to and beyond the IC50 of rupintrivir, an irreversible inhibitor of the 3C 
protease (Binford, et al. 2007). The T7-3C phage were still able to lyse these rupintrivir-
treated E. coli cells, presumably because the rupintrivir was not making it into the E. coli 
cells at a concentration by which 3C protease inhibition halted T7-3C life cycling.   
Another expansion of this T7-protease system is through using it as a means of 
profiling non-canonical target cleavage sites. This was done on a proof-of-concept level, 
by using an NNS library at the codon coding for the P2 residue in the canonical 3C target 
cleavage site in the pPOS5-TrxA-gene-10-3C constructs to create an N=32 library. After 
making these now-single-mutant away from the canonical 3C cleavage site (a 
LEVLXQ/GP library), plasmids were transformed into E. coli cells, plated, and 
individual colonies were picked and used to grow up each well in a 96-well plate (a N=32 
library can be 95% covered with a sampling of 94). These O/N cultures were used to 
grow up fresh cells in 1mM IPTG-induced 2xYT, as to stimulate production of the TrxA-
cleavage site-gene 10 proteins, and each well was then inoculated with T7-3C phage and 
placed on a plate reader. Lysis curves were determined and the clonal overnight cells 
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(from which were derived the freshly induced cells which were successfully lysed) of 
those that had lysed on the plate reader were then miniprepped and sequenced as to 
determine the target cleavage sequence. It was found that the 3C target P2 residue in this 
system could change from a phenylalanine (F) to a glycine (G), valine (V), arginine (R), 
and glutamic acid (E). Though there are other, higher through-put assays for identifying 
protease specificity, this method may be particularly useful for helping decide paths 
towards evolving and targeting protease mutants against non-canonical cleavage targets 
(O'Donoghue, et al. 2012).   
 Finally, the efforts here to mutate proteases in response to non-canonical cleavage 
targets were inherently limited in that all used a single starting protease sequence. In 
theory, this system would greatly benefit from the use of a library of proteases as a 
starting point instead of just one. The relatively low recombination rate between 
bacteriophage T7 and even a high copy-number plasmid makes this route an implausible 
path forward for library generation (Kiro, et al. 2014). Another strategy used by others to 
engineer genomic additions to bacteriophage T7 has been the assembly of its genome on 
a plasmid in yeast, followed by prepping out of said plasmid, and finally transformation 
into an E. coli cell-type specifically adapted for the transformation of large plasmids in 
which the bacteriophage will “boot” and begin its life cycling (Ando, et al. 2015). Two 
attempts were made specifically trying to clone wild-type bacteriophage T7 in this 
manner, using 8 replicates each. These replicates (though having evidence of the 
bacteriophage T7 genome detected by PCR) nonetheless failed to boot when transformed 
into E. coli cells. Anecdotally, others have had technical issues when attempting to do the 
same thing. As such, this method in and of itself does not seem like it would be a useful 
way to generate protease libraries in bacteriophage T7. This scheme may be able to be 
successfully adapted, however, if one could insert any gene of interest into the 
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bacteriophage genome within a yeast plasmid using yeast‟s ability of the yeast I-SceI 
restriction enzyme to select particularly those T7 genomes which had experienced 
recombination (Plessis, et al. 1992). These now high-percentage of recombined T7-
genome-in yeast plasmids could then be prepped out and successfully booted up when 
added to a cell-free transcription-translation system, which has already been shown to 
facilitate bacteriophage T7 genome replication, synthesis, and assembly of infective 
virons (Shih, et al. 2005). 
 
Conclusion: the deficiencies, power, and potential of this T7-protease system 
The creation of this T7-protease system led to multiple lessons regarding the 
nature and use of split-T7 RNA polymerase, bacteriophage T7 recombination, functional 
fusions with the major capsid protein, the plasticity of TEV and 3C proteases, and the 
overall ability to rationally engineer control of bacteriophage life cycling. Though 
nominally successful in being able to rationally design control over the bacteriophage life 
cycling, it did not achieve a main goal of acting as a facile directed evolution platform for 
the directed evolution of proteases towards non-cognate target substrates. Many lessons 
were learned in this process. Chiefly, it would seem as if the limited sequence constrains 
which result from using only one protease variant, together with a limited sampling of 
sequence space as a result of the natural T7 DNA polymerase error rate (which, 
functionally can sample only those amino acids within point mutational distance of the 
original/starting sequence). It is tempting to speculate that the results, beyond the implied 
emergent generalists resulting from the TEV non-canonical substrate selections, would be 
different had the same or nearly the same library size as is typically brought to bear in E. 
coli-based directed evolution schemes (approximate library size of 10
8
) was also used in 
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this system. The difficulty in creating such a library in bacteriophage as well as a 
potential solution is stated in the previous section of this chapter.  
Beyond library size, an additional deficiency of this T7-protease system as a 
directed evolution system is a result of its read-out: it is difficult to know in the absence 
of sequencing which mutations have occurred in the protease of interest and, additionally, 
difficult to know “what went wrong” when macroscopic lysis does not occur. Indeed, it 
often takes five or so passages before one can be sure that the T7-protease viruses have or 
have not enriched microscopically enough to actually be detected macroscopically. These 
two deficiencies, admittedly, have no very easy solution. One final noteworthy deficiency 
of this system is inherent to the bacteriophage life cycling: T7 must infect and produce 
virions while E. coli cells are in logarithmic (i.e. growth) phase (Molineux 2006). The 
exact mechanism behind this limitation is unknown and is also an admitted deficiency of 
this T7-protease viral life cycling system for the evolution of proteases.  
Having conceded some of the limitations of the T7-protease system is it worth 
noting some of its power and potential. This T7-protease system, unlike many, many 
other continuous evolution systems, did not cheat, that is, it did not find unintended ways 
(such as recombination) around of selecting what it was selected on. It is relatively easy, 
especially in relation to PACE, to turn rounds/passage. A compelling observation speaks 
to the unique mutational sampling of this system in how it was run: at no point in 
sequencing any protease variant was there observed a silent mutation. Overall, though a 
panel of orthogonal proteases derived from the same ancestral protease was not achieved, 
the creation and orthogonal use of T7-TEV and T7-3C can enable selective cell killing 
and also suggests that the system in extensible to other proteases. Though unsuccessful in 
proof of concept, a T7-protease system may enable rapid screening of protease inhibitors 
or the enrichment of protease mutants in response to protease inhibitors. Beyond 
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proteases, simple modifications to a T7 life cycle-constraining evolution system can be 
envisioned where the replication of bacteriophage T7 is reliant upon other genes of 
interest such as recombinases, tRNAs, and tRNA-synthetases. Overall, this system is 
another step in the direction of utilizing the rational design and synthesis tools associated 
with synthetic biology together with the power of evolutionary pressure in order to drive 
novel viral creation and synthetic viromics. 
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Figures 
 
Figure 3.1: Depiction of canonical TEV protease cleavage site 
 
 
 
Figure 3.1: Depiction of canonical TEV protease cleavage site and the self-cleavage site 
on the TEV protease on which it has activity.  
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Figure 3.2: Ligand-receptor interaction map of TEV protease 
 
 
 
Figure 3.2: Ligand-receptor interaction map of TEV protease complexed with its 
canonical ENLYFQ product, based on PDB: 1LVM, created using Molecular Operating 
Environment.  
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Table 3.1: OD600 readings of BL21 E. coli cells containing each of the three split-T7 
RNAP constructs 
 
 
 
 
Table 3.1: Table showing the OD600 readings of BL21 E. coli cells containing each of the 
three split-T7 RNAP constructs under the control of a LacUV5 promoter together with a 
pTET15A plasmid containing TEV protease under a pTetO promoter. O/N E. coli cells 
were diluted into 2mLs of 2xYT with proper antibiotics and grown for one hour to mid-
log phage at which point phage were added. Time recorded in minutes after infection. + 
phage= MOI  0.1 T7Δ1 phage, +tet = induction of transcription from the pTetO promoter 
by 200ng/mL anhydrous tetracycline induction, +lac= induction of transcription from the 
LacUV5 promoter with 1mM IPTG induction.  
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Figure 3.3: Scheme for T7Δ10-based protease system/selection. 
 
 
 
Figure 3.3: Scheme for T7Δ10-based protease system/selection. A protease of interested 
(or libraries thereof) is cloned into a plasmid with 50-100bp regions flanking each side of 
the desired insertion site in the T7Δ10 genome. T7Δ10 phages will infect E. coli cells 
permissive to its replication (has gene 10 supplied by another plasmid) and a fraction of 
these will recombine such that the proteases are inserted into the T7 genome. These 
resulting cells are used to infect the E. coli selection plasmid where one of two events 
will occur: 1) a functional protease will cleave the protease-cleavage-site linker between 
the major capsid protein and theoredoxin A (TrxA) allowing successful phage replication 
to occur or 2) non-functional proteases will not cleave the protease-cleavage-site linker 
and not allow major capsid proteins to assemble and allow for phage replication. After a 
number of passages, the lysate (with the successfully replicating T7-protease phages) will 
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be subjected to PCR using primers flanking the proteases in the T7 genome to recover 
successful variants for sequencing or additional selection. 
 
Table 3.2: OD600 readings of BL21 E. coli cells containing the gene 10 only, the gene 10-
TEV-cleavage-site-TrxA fusion, or the TrxA-TEV-cleavage-site-gene 10 fusion 
constructs 
 
Table 3.2: Table showing the OD600 readings of BL21 E. coli cells containing the gene 10 
only, the gene 10-TEV-cleavage-site-TrxA fusion, or the TrxA-TEV-cleavage-site-gene 
10 fusion construct under the control of a LacUV5 promoter together with a pTET15A 
plasmid containing TEV protease under the pTetO promoter. O/N E. coli cells were 
diluted into 2mLs of 2xYT with proper antibiotics and grown for one hour to mid-log 
phage at which point phage were added. Time recorded in minutes after infection. + 
phage= MOI  0.1 T7Δ1 phage, +tet = induction of transcription from the pTetO promoter 
by 200ng/mL anhydrous tetracycline induction, +lac= induction of transcription from the 
LacUV5 promoter with 1mM IPTG induction.   
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Table 3.3: Mutations resulting from initial passaging of TEV-S219P 
 
Table 3.3: Mutations resulting from initial passaging of TEV-S219P on 1mM induced 
pLUV-TrxA-gene-10 for 10 passages 
 
Table 3.4: Mutations resulting from passaging TEV-S219P in presence of Flanked TEV-
Fast 
 
Table 3.4: Mutations resulting from passaging TEV-S219P in presence of Flanked TEV-
Fast for five passages and then five more passages on 1mM induced pLUV-TrxA-gene-
10, MOI 0.1 
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Table 3.5: Mutations resulting from passaging TEV-S219V 
 
Table 3.5: Mutations resulting from passaging TEV-S219V on 1mM induced pLUV-
TrxA-gene-10, MOI 0.1 for first 10 passages at MOI 0.1 then 10 more passages on 
100uM induced pLUV-TrxA-gene-10, MOI 0.01 
 
Table 3.6: Mutations resulting from passaging TEV-Fast 
 
Table 3.6: Mutations resulting from passaging TEV-Fast on 1mM induced pLUV-TrxA-
gene-10, MOI 0.1 for first 10 passages at MOI 0.1 then 10 more passages on 100uM 
induced pLUV-TrxA-gene-10, MOI 0.01 
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Figure 3.4: PyMOL rendering of the TEV protease 
 
 
 
Figure 3.4: PyMOL rendering of the TEV protease (green) complexed with its canonical 
substrate (orange). The Asn177 residue (red) in TEV protease interacts with the P6 Glu 
of TEV protease substrate (orange). The N177T mutant is hypothesized to stabilize the 
binding of TEV protease to its substrate. (PDB ID: 1LVB) 
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Figure 3.5: Lysis curves comparing various TEV-phage populations at various passages 
 
 
 
Figure 3.5: Lysis curves comparing various TEV-phage populations at various passages. 
Above, freshly titered phages used at an MOI of 0.1 to infect 1mM IPTG-induced pLUV-
TrxA-gene 10 BL21 E. coli cells. Error bars represent standard deviations. 
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Figure 3.6: Lysis curves comparing various TEV-phage populations at various passages  
 
 
 
Figure 3.6: Lysis curves comparing various TEV-phage populations at various passages. 
Above, freshly titered phages used at an MOI of 0.1 to infect 10uM IPTG-induced 
pLUV-TrxA-gene 10 BL21 E. coli cells. Error bars represent standard deviations.  
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Figure 3.7: Scheme depicting the progression from initial recombination of S219V into 
bacteriophage T7 to the creation of each EΔW-adapted, YΔE-adapted, YΔH-adapted, and 
QΔH-adapted T7-TEV phage populations. 
 
 
 
Figure 3.7: Scheme depicting the progression from initial recombination of S219V into 
bacteriophage T7 to the creation of each EΔW-adapted, YΔE-adapted, YΔH-adapted, and 
QΔH-adapted T7-TEV phage populations. These populations (with the exception of the 
QΔH-adapted one) followed the same path whereas 10 passages were done on each 
respective target-containing cells at 1mM ITPG induction and an MOI of 0.1, then 10 
passages at 1mM IPTG induction and an MOI of 0.01, and finally 10 passages at 1uM 
IPTG induction and an MOI of 0.01. The QΔH-adapted population was not able to lyse 
target cells at 1uM IPTG induction and thus the series of passages were omitted.  
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Figure 3.8: Lysis curves of wild-type (S219V) TEV-adapted phage population on various 
single-point mutation TEV protease targets 
 
 
 
Figure 3.8: Lysis curves of wild-type (here, defined as S219V) TEV-adapted phage 
population on various single-point mutation TEV protease targets. Freshly titered phages 
used at an MOI of 0.1 to infect 1mM IPTG-induced pLUV-TrxA-gene 10 BL21 E. coli 
cells. Error bars represent standard deviations.  
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Figure 3.9: Lysis curves of EΔW TEV-adapted phage population on various single-point 
mutation TEV protease targets 
 
 
 
Figure 3.9: Lysis curves of EΔW TEV-adapted phage population on various single-point 
mutation TEV protease targets. Freshly titered phages used at an MOI of 0.1 to infect 
1mM IPTG-induced pLUV-TrxA-gene 10 BL21 E. coli cells. Error bars represent 
standard deviations. 
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Figure 3.10: Lysis curves of YΔH TEV-adapted phage population on various single-point 
mutation TEV protease targets 
 
 
 
Figure 3.10: Lysis curves of YΔH TEV-adapted phage population on various single-point 
mutation TEV protease targets. Freshly titered phages used at an MOI of 0.1 to infect 
1mM IPTG-induced pLUV-TrxA-gene 10 BL21 E. coli cells. Error bars represent 
standard deviations. 
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Figure 3.11: Lysis curves of YΔE TEV-adapted phage population on various single-point 
mutation TEV protease targets 
 
 
 
Figure 3.11: Lysis curves of YΔE TEV-adapted phage population on various single-point 
mutation TEV protease targets. Freshly titered phages used at an MOI of 0.1 to infect 
1mM IPTG-induced pLUV-TrxA-gene 10 BL21 E. coli cells. Error bars represent 
standard deviations. 
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Figure 3.12: Lysis curves of QΔH TEV-adapted phage population on various single-point 
mutation TEV protease targets 
 
 
 
Figure 3.12: Lysis curves of QΔH TEV-adapted phage population on various single-point 
mutation TEV protease targets. Freshly titered phages used at an MOI of 0.1 to infect 
1mM IPTG-induced pLUV-TrxA-gene 10 BL21 E. coli cells. Error bars represent 
standard deviations. 
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Table 3.7: Mutations in individual T7-TEV phage isolates from EΔW, YΔH, YΔE, and 
QΔH TEV-adapted populations. 
 
 
 
Table 3.7: Mutations in individual T7-TEV phage isolates from EΔW, YΔH, YΔE, and 
QΔH TEV-adapted populations.  
 
Table 3.8: OD600 readings of BL21 E. coli cells containing the TrxA-3C-cleavage-site-
gene 10 fusion construct 
 
Table 3.8: Table showing the OD600 readings of BL21 E. coli cells containing the TrxA-
3C-cleavage-site-gene 10 fusion construct under the control of a LacUV5 promoter 
together with a pTET15A plasmid containing rhinovirus 3C protease under the pTetO 
promoter. O/N E. coli cells were diluted into 2mLs of 2xYT with proper antibiotics and 
grown for one hour to mid-log phage at which point phage were added. Time recorded in 
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minutes after infection. + phage= MOI  0.1 T7Δ10 phage, +tet = induction of 
transcription from the pTetO promoter by 200ng/mL anhydrous tetracycline induction, 
+lac= induction of transcription from the LacUV5 promoter with 1mM IPTG induction.   
 
Figure 3.13: Picture of 3C protease and 3C target induced T7Δ10 infected E. coli cells 
 
 
 
Figure 3.13: Picture of 3C protease and 3C target induced T7Δ10 infected E. coli cells in 
order as listed in the figure above at one hour post infection.  
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Figure 3.14: Scheme depicting optimal orthogonality of T7-protease phage life cycling 
 
 
 
Figure 3.14: Scheme depicting optimal orthogonality of T7-protease phage life cycling. 
Hypothetically, T7-protease dependent replication can occur in a protease target-
dependent manner which allows one T7-protease type to replicate in cells containing its 
cognate target construct while not replicating in cells containing the other’s target 
construct.  
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Figure 3.15: Lysis curves of T7-TEV and T7-3C phages on either TEV target or 3C target 
 
 
 
Figure 3.15: Lysis curves of T7-TEV and T7-3C phages on either TEV target or 3C 
target. Freshly titered phages used at an MOI of 0.1 to infect 1mM IPTG-induced pLUV-
TrxA-gene 10 BL21 E. coli cells. Results shown here are in singlicate though the same 
pattern of lysis holds for the range of MOIs (see Figures 3.16 and 3.17).  
 
 
 
 
 
 
 
 
 
 
 127 
Figure 3.16: Lysis curves for T7-TEV phage on 1mM induced TEV target or 3C target at 
various MOIs 
 
 
 
 
Figure 3.16: Lysis curves for T7-TEV phage on 1mM induced TEV target (above) or 3C 
target (below) at various MOIs. 
 128 
Figure 3.17: Lysis curves for T7-3C phage on 1mM induced 3C target or TEV target at 
various MOIs 
 
 
 
 
Figure 3.17: Lysis curves for T7-3C phage on 1mM induced 3C target (above) or TEV 
target (below) at various MOIs. 
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CONCLUSION 
This work describes the findings from three projects in which arbitrarily 
engineered parts or circuits were used as design constraints to shape and study the 
evolutionary trajectory of bacteriophage T7. In the first project, we demonstrated that is 
was possible to predict much of the evolutionary trajectory of bacteriophage promoter 
identity mutations in response to a synthetically-created RNA polymerase. In the second 
project, we showed that bacteriophage populations altered their transcriptional apparatus 
such that the synthetic polymerase (rather than promoters) picked up subsequent 
mutations and in doing so reached the same outcome of promoter generality in two 
different ways.  In the third project, a system of bacteriophage T7 life-cycling dependent 
on foreign protease activity was created and explored, eventually showing extensibility 
which enabled selective cell killing. Overall, these projects are another step in the 
direction of utilizing the rational design and synthesis tools associated with synthetic 
biology together with the power of evolutionary pressure in order to drive novel viral 
creation, evolution, and synthetic viromics. 
This work shows how the use of laboratory evolution and directed evolution can 
lead to unexpected outcomes. This work demonstrates both the power and speed of 
bacteriophage T7 evolution in the laboratory setting but also some of the limitations to its 
plasticity. This work is a small addition to the work of many others which demonstrates 
how bacteriophages, an important biological entity since the founding of molecular 
biology, together with the newest tools and techniques to read, write, and edit genomes, 
will continue to be relevant and useful for evolutionary biology and biotechnology well 
into the future. Finally, in the unending tension between reductionism and holism, this 
work provides evidence that although the ability to rationally design biology is important, 
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various ways to rationally control and direct evolution offer a complementary strategy to 
the systematization of synthetic biology. 
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Appendix  
Bacteriophage T7 by the Numbers 
It is sometimes helpful to remind oneself of the quantitative aspects of an 
organism of study, specifically, regarding information such as its genome size, number of 
protein coding domains, and life cycle. This section lists a few of the interesting numbers 
associated with the bacteriophage T7 and derives a few numerical answers to relevant 
questions which, although assuming much and oversimplifying to allow back-of-the-
envelope calculations, lead to interesting and potentially useful conclusions.  
Goal: Determine… 
 
1) Rate of T7 DNA replication relative to PCR: 
PCR: 15-60 seconds/kB → 17-67 bp/sec, requires thermocycling  
T7 bacteriophage: 220 (+/-) 80 bp/sec, isothermal (30-37 °C) (Lee, et al. 2006) 
 
2) How quickly bacteriophage T7 would lyse a mid-log phage culture of E. coli with the 
volume of the world’s oceans: 
Assume: Volume of world‟s oceans = 1.3324x109 km3 (Smith 2010), km3 
seawater=10
12
 liters,  
Assume: E. coli cells @ OD~1= 10
8
 cells/mL (10
11
 cells/L) 
Assume: Bacteriophage T7 burst size = 260 (De Paepe and Taddei 2006) and lysis 
time is ~ 30 minutes  
Assume: Well-mixed ocean, with no co/super-infection, such that one phage 
perfectly enters the next uninfected cell at a time immediately after previous cell lysis  
1.3324x10
9
 km3 x 10
12
 liters = 1.334x10
21
 liters in world‟s oceans    
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1.334x10
21
 liters x 10
11
 cells/liter = 1.334x10
32
 total E. coli cells  
The amount of infectious “cycles” needed to lyse these cells can be determined 
from the following equation:  
(Burst size x Number of starting phage)“cycles” of infection = total number of 
cells to be killed 
Starting with one bacteriophage T7,  
(260 x 1 ) “cycles” of infection = 1.334x1032    
“cycles” of infection x log (260) = log (1.334x1032)  
“cycles” of infection = log (1.334*1032) / log (260) 
“cycles” of infection = 13.3 → 14 “cycles” of infection  
14 “cycles” of infection x (30 minutes / “cycle” of infection) = 420 minutes = 7 
hours  
Calculation of end-to-end length of all of those T7 genomes  
Assume: T7 genome ~ 40kB (Calendar 2006), each base pair is 0.34nm in length 
(Watson and Crick 1953) and the diameter of the observable universe = 93 billion light 
years (8.798x10
23
 km) (Bars, et al. 2009) 
Number of total T7 genomes = number of total cells x burst size 
Number of total T7 genomes =  (1.334x10
32
) x 260 = 3.46x10
34
  
10bp = linear length of 3.4nm 
10kB = 3.4um x 4 = 13.6um = 1.36 x 10
-5
 m = length of one T7 genome 
Total genomes x length of T7 genome = end-to-end length of T7 genomes from 
the Earth‟s oceans volume of lysed E. coli cells  
(3.46x10
34
 genomes) x (1.36 x 10
-5
 m/genome) =  4.71x10
29
 m =  4.71x10
26
 km 
End-to-end length of T7 genomes from the Earth‟s oceans volume of lysed E. coli 
cells / Diameter of observable universe =   (4.71x10
26
 km)/(8.798x10
23
 km) = 535 times  
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3) The theoretical rate of sampling of sequence space as bacteriophage T7 lyses cells and 
naturally mutates: 
Assume: T7 DNA polymerase error rate 10
-8
 (cited values 10
-6
 to 10
-8
) (Kunkel 
2004) and that mutations would occur evenly at all locations in the T7 genome 
1 T7 phage enters 1 E. coli cell = 260 T7 phage progeny (i.e. burst size). So, 
40,000bp x 260 phages = 1.04 x 10
7
 bp replicated. Given the T7 error rate of 10
-8
, there 
will be errors on the scale of 1 phage in every 10 cells that lyse. In a 10
8
 E. coli cells/mL 
culture, complete lysis would generate a pool of approximately 10
10
 phage genomes 
which, collectively, would mutationally sample each nucleotide position 250 times (10
7
 
mutant phage with single error / 40,000bp = 250).     
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